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Abstract 
RNA interference (RNAi) is a highly efficient and specific posttranscriptional gene silencing 
process, which can be triggered by small interfering RNA. The efficiency and specificity of 
this process makes siRNA a powerful tool for gene therapy. However, the use of siRNA is 
hampered by its rapid degradation and poor cellular uptake. A variety of carriers for example, 
virus, lipid, polymer, peptides, and nanoparticles, have been developed to protect siRNA and 
maximize its therapeutic effects. Among these carriers, peptides have emerged as a 
promising candidate due to their intrinsically rapid and highly efficient internalization and 
their typically low toxicity. 
The amphipathic, cationic peptide C6 (sequence: Ac-RLLRLLLRLWRRLLRLLR-NH2) 
was previously designed and studied in our group. C6 achieved significant siRNA cellular 
uptake but induced low gene silencing, possibly due to siRNA entrapment in endosomes.  In 
order to enhance endosomal release of siRNA, two strategies were incorporated to design a 
new peptide: (1) adding more pore-formation moieties, such as tryptophan; (2) including pH-
sensitive moieties, such as histidine. The resulting peptide C6M3 (sequence: Ac-
RLWHLLWRLWRRLHRLLR-NH2) incorporated three tryptophan residues and two 
histidine residues that could induce the so called “proton sponge effect”. Similar to C6, 
C6M3 could encapsulate all the free siRNA (siRNA: 5 µM) at minimal molar ratio 10/1. 
Moreover, C6M3 alone adopted a defined structure-α-helical secondary structure that could 
enhance peptide-cell membrane interaction, while C6 could not form a secondary structure. 
C6M3-siRNA complexes displayed a particle diameter of 80-100 nm, which was smaller 
than that of C6-siRNA complexes. Compared to C6 (Ka: 9.23x106 M-1), C6M3 had stronger 
binding affinity with siRNA (Ka: 8.59x108 M-1) in water at room temperature, which was 
confirmed by isothermal titration calorimetry (ITC). Moreover, in CHO-K1 monolayer cell 
culture, the GAPDH gene silencing efficiency induced by C6M3-siRNA complexes was 
significant (68% ±2).  Effective in vivo RNAi was achieved in a human non-small lung 
tumor xenograft model through intratumoral injection of the C6M3-Bcl-2 siRNA complexes 
  v 
(molar ratio: 60/1). This treatment induced a marked tumor suppression, with an inhibition 
rate of 55%±3, through suppression of antiapoptotic Bcl-2 protein in mice.  
CADY (sequence: Ac-GLWRALWRLLRSLWRLLWRA-cysteamide), a reported 
amphipathic peptide, has been shown to deliver nucleic acids, peptides, and proteins into 
various cells. The high potency of this peptide is strongly related to its tryptophan rich 
property, helical conformation, and amphipathic character. The segment GLWRA seems to 
play a role in the potency of CADY. This information, associated with the sequence of 
C6M3, and also alanine amino acid being reported to facilitate helical conformation, led to 
the design of GL family peptides. After pre-screening for transfection activity, a promising 
candidate GL1 was identified and selected for further evaluation. Compared to C6M3, GL1 
(sequence: Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2) included a higher amount of 
tryptophan (4 vs. 3) to enhance peptide-membrane interaction, and three alanine (A) amino 
acids to contribute to helical conformation. GL1 could encapsulate all the siRNA (siRNA: 5 
µM) at minimal molar ratio 15/1, displaying a spherical shape with a particle diameter of 80-
100 nm. GL1 adopted α-helical secondary structure in water and exhibited strong binding 
affinity with siRNA (Ka: 4.47x108 M-1) confirmed by circular dichroism (CD) spectroscopy 
and ITC respectively. In monolayer culture of CHO-K1 cells, GL1 could deliver siRNA to 
95% of the cells even at molar ratio 20/1 (siRNA: 50 nM), while C6M3 required a higher 
molar ratio (40/1) to achieve the same result.  This difference may be due to the higher 
amount of tryptophan and the GLWRAW segment in the GL1 sequence. Interestingly, GL1 
induced a lower GAPDH gene silencing efficiency (49% ±2) than C6M3, possibly because of 
lack of efficient endosomal release of siRNA. Both GL1 and C6M3 achieved minimal 
cytotoxicity (<10% ±2) with siRNA concentration of 50 nM. As monolayer cell culture lacks 
the 3D features of an in vivo model, multicellular tumor spheroids (MCTS), an intermediate 
model between traditional monolayer cell culture and in vivo model, are developed. CHO-K1 
MCTS were established utilizing a hanging drop method and used for investigating the 
efficacy of GL1-siRNA complexes.  This approach induced markedly suppression of 
GAPDH gene expression (50%±2) with minimal cytotoxicity (<5%±2). Following 
procedures of in vivo studies mentioned above, GL1-Bcl-2 siRNA complexes (molar ratio: 
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60/1) caused a tumor inhibition rate of 54%±4 through downregulation of antiapoptotic Bcl-2 
protein, which was similar to that of C6M3-Bcl-2 siRNA complexes. 
Recently, stearylation has proven to be successful in increasing the transfection efficiency 
of cell penetrating peptides (CPPs) for DNA delivery or that of polyethyleneimine (PEI) for 
siRNA delivery. A stearyl moiety is believed to play an essential role in enhancing 
compaction of DNA, cellular uptake, and endosomal escape. Therefore, a new design 
strategy incorporating stearic acid conjugation in peptide sequence was applied. STR-HK 
(sequence: C18–HHHPKPKRKV-NH2) consisted of a stearyl moiety enhancing peptide-
siRNA/cell membrane interaction, three histidine inducing “proton sponge effect”, a 
cytoplasm localization sequence (PKPKRKV) contributing to cytoplasma localization of the 
complexes, and the cationic amino acids (K & R) facilitating the peptide-siRNA binding 
through electrostatic interaction. STR-HK required minimal molar ratio 15/1 to fully 
encapsulate siRNA (siRNA: 5 µM) and the complexes displayed a spherical shape with a size 
distribution of 80-140 nm in diameter. Note that STR-HK adopted ß sheet secondary 
structure in water and exhibited strong binding affinity with siRNA (Ka: 3.73x105 M-1) 
confirmed by CD and ITC respectively. Interestingly, at molar ratio 20/1 (siRNA: 50 nM), 
STR-HK could deliver siRNA to ~20% of the CHO-K1 cells, which was significantly lower 
than that of C6M3 and GL1. Increasing the molar ratio to 40/1, STR-HK achieved similar 
cellular uptake as C6M3. The possible reason was that a high amount of stearyl moieties 
could enhance cellular uptake. In monolayer culture of CHO-K1 cells, STR-HK achieved 
higher GAPDH gene silencing efficiency (75%±2) than C6M3 and GL1 with minimal 
cytotoxicity (<10%±2). Following similar procedures of in vivo treatment mentioned above, 
STR-HK-Bcl-2 siRNA complexes (molar ratio: 60/1) resulted in a tumor inhibition rate of 
63%±3 via downregulation of Bcl-2 protein in mice. This tumor inhibition rate was higher 
than that of C6M3/GL1-Bcl-2siRNA complexes.  
This thesis focuses on characterization and evaluation of the three newly designed peptides 
as potential siRNA delivery systems. These three peptides were designed according to the 
following strategies: (1) modification of the amphipathic, cationic peptide C6 with 
tryptophan and histidine in the sequence; (2) adoption of parts of peptides CADY and C6M3 
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along with addition of an amphipilic segment; (3) conjugation of a stearyl moiety to peptide 
sequence. Among the three peptides, C6M3 could encapsulate all the free siRNA (siRNA at 
5 µM) with the lowest molar ratio (10/1) and exhibited the strongest binding affinity with 
siRNA (Ka: 8.59x108 M-1). The three peptides adopted secondary structures: C6M3 and GL1 
adopted helical structure and STR-HK adopted ß sheet structure. The peptide-siRNA 
complexes all assumed a spherical shape and induced minimal cytotoxicity in CHO-K1 cells 
(<10%±3). To achieve optimum gene silencing efficiency, the peptide/siRNA molar ratio 
needed to be optimized. STR-HK-siRNA complexes at molar ratio 60/1 achieved the highest 
GAPDH gene silencing efficiency (75%±2) in monolayer culture of CHO-K1 cells. In the 
human non-small cell lung tumor xenograft model, the STR-HK-siRNA complexes induced 
the highest tumor inhibition rate (63%±3). These data indicated the advantage of the peptide 
STR-HK. However, the potency of these three peptides could be further evaluated in other 
cell lines and in vivo models through systemic administration of the peptide-siRNA 
complexes. 
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Chapter 1 
Introduction 
1.1 Overview 
The term RNA interference (RNAi) was first coined after the discovery in the nematode 
Caenorhabditis elegans that double-stranded RNAs (dsRNAs) can trigger silencing of 
complementary messenger RNA (mRNA) sequences[1]. The mechanism by which RNAi 
inhibits the conversion of mRNA into protein is briefly reviewed here. Small interfering 
RNA (siRNA) and micro RNA (miRNA) are central to RNA interference. Double-stranded 
RNA is recognized by an RNase type III enzyme, Dicer, and cleaved into small fragments of 
21- 23 nucleotides called siRNAs. Each siRNA is unwound into a sense (passenger) strand 
and an antisense (guide) strand with respect to the target mRNA (Figure 1.1). siRNA binds to 
a protein complex called RNA-induced silencing complex (RISC) and the passenger strand is 
degraded, while the guide strand is directed to the 3’ untranslated region (UTR) of the 
complementary target mRNA. A cleavage enzyme within RISC (argonaute 2) degrades the 
target mRNA, thus preventing translation. miRNAs also exist in cells and are pre-processed 
by a nuclear RNase III (Drosha) before export into the cytoplasm by nuclear transport 
receptor complexes. Due to limited complementarily to the target mRNA, miRNAs do not 
lead to the cleavage of mRNA with the RISC but, instead, result in translational suppression 
[2]. 
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Figure 1.1. Mechanism of RNAi following intracellular dsRNA delivery. Adapted from[2]. 
Reprinted with permission from Nature. 
 
Since the discovery of RNAi, there has been an explosion of interest in using this 
technology for basic and applied research and RNAi has been one of the most promising new 
approaches for disease therapy. The list of diseases that may be treated by RNAi is extensive, 
including cancers, Parkinson’s disease [3], HIV infection [4], age-related macular 
degeneration [5], type 2 diabetes [6], obesity [7], hypercholesterolemia [8], and rheumatoid 
arthritis [9]. 
Despite this promising research, a number of problems remain in the realization of siRNA 
therapeutics. Although several human clinical trials are being conducted, most of these 
treatments are limited to local delivery of siRNAs, such as direct injection into the eye or 
skin. Targeting specific genes in tissues and organs is best facilitated with systemic delivery 
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during treatment. The main limitations in siRNA therapeutics are instability of naked siRNA 
under physiological conditions, rapid clearance from the blood stream, inability to cross 
targets cell membranes and gain access to the intracellular environment at the clinically 
relevant dose. These drawbacks are intrinsically related to some of the unfavorable 
physicochemical properties of siRNA molecules, including large molecule weight, negatively 
charged surface, hydrophilicity, sensitivity to nuclease degradation and short plasma half-life 
of less than ten minutes [10]. Thus, the development of siRNA therapeutics requires an 
efficient and safe delivery system. 
In search for effective siRNA delivery systems, a number of materials have been 
attempted, including virus vectors, liposomes, lipoplexes, polymers, and peptides [11,12]. 
Among them, cell-penetrating peptides (CPPs) have been utilized for intracellular delivery of 
a variety of macromolecules, including proteins, peptide nucleic acids (PNA), and siRNAs 
[13]. 
In this research, three newly designed amphipathic, cationic peptides were characterized 
and their potential as a siRNA delivery system was evaluated. Biophysical, spectroscopic, 
thermodynamic, and microscopic techniques were used to characterize the interaction 
between peptide and siRNA. The uptake, gene silencing efficiency, and cytotoxicity of the 
designed peptides in complex with siRNA were investigated. 
1.2 Research Objectives 
The goal of this study was to develop an effective and safe peptide based siRNA delivery 
system. To achieve this goal, three newly designed peptides were investigated including their 
siRNA binding capacity, gene silencing efficiency, and cytotoxicity in mammalian cells and 
a xenograft mouse model. Compared to our group’s previous work on peptide based siRNA 
delivery systems, this thesis presented different peptide design strategies to further enhance 
the peptide’s delivery efficacy, developed a three dimensional (3D) culturing model, and 
evaluated the delivery efficacy of the peptide in this 3D model. The specific objectives of this 
thesis are listed as follows: 
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1. Screen the modified/designed amphipathic cationic peptides to evaluate their 
siRNA transfection efficiency and cytotoxicity. 
2. Characterize the binding between peptides and siRNAs, the size, zeta potential, 
secondary structure, and morphology of peptide-siRNA complexes;  evaluate the 
uptake, transfection efficiency of siRNA delivered by peptides and the cytotoxicity 
of peptide-siRNA complexes in traditional monolayer cell culture envrionment. 
3. Establish a three dimensional cell culture model—multicellular tumor spheroids—
to investigate the uptake gene silencing efficiency, and cytotoxicity of the peptide-
siRNA complexes. 
4. Evaluate the antitumor activity of the peptide-siRNA complexes in a mouse 
xenograft tumor model. 
1.3 Outline of the Thesis 
The thesis consists of seven chapters. The scope of each chapter is listed as follows: 
Chapter 1 gives an in introduction to RNA interference process, siRNA therapeutics, gene 
delivery systems, and the potential of peptides as siRNA delivery systems. The research 
objectives and the outline of the thesis are also given. 
Chapter 2 provides a review of siRNA therapeutics and current siRNA delivery systems. 
Uptake pathways and mechanisms of endosomal escape are also reviewd. 
Chapter 3 introduces peptide C6M3, a modified version of our previously studied peptide 
C6. The modification strategy and physicochemical characteristics of C6M3 in complex with 
siRNA are discussed. The uptake, gene silencing efficiency, and cytotoxicity of the 
complexes are also reported. 
Chapter 4 introduces peptide GL1. The design strategy and physicochemical properties of 
GL1 and the uptake, gene silencing efficiency, and cytotoxicity of the GL1-siRNA 
complexes are reported. 
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Chapter 5 investigates the potential of GL1 as a delivery system in multicellular tumor 
spheroids and the therapeutic effects of GL1-siRNA complexes in a tumor xenograft tumor 
model. 
Chapter 6 introduces peptide STR-HK, which incorporated the conjugation of stearyl 
moiety in the sequence. The physicochemical properties of this peptide and the uptake, gene 
silencing efficiency, and cytotoxicity of the complexes are investigated. 
Chapter 7 presents the original contributions of this research and recommendations for 
future work. 
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Chapter 2 
Literature Review 
2.1 RNA Interference 
The term RNA interference (RNAi) was first coined after the discovery in the nematode 
Caenorhabditiselegans that double-stranded RNAs (dsRNAs) can trigger silencing of 
complementary messenger RNA (mRNA) sequences [1]. The mechanism by which RNAi 
inhibits the conversion of mRNA into protein is briefly reviewed here. Small interfering 
RNA (siRNA) and micro RNA (miRNA) are central to RNA interference. Double-stranded 
RNA is recognized by an RNase type III enzyme, Dicer, and cleaved into small fragments of 
21 - 23 nucleotides called siRNAs. Each siRNA is unwound into a sense (passenger) strand 
and an antisense (guide) strand with respect to the target mRNA (Figure 2.1). siRNA binds to 
a protein complex called RNA-induced silencing complex (RISC) and the passenger strand is 
degraded, while the guide strand is directed to the 3’ untranslated region (UTR) of the 
complementary target mRNA. A cleavage enzyme within RISC (argonaute 2) degrades the 
target mRNA, thus preventing translation. miRNAs also exist in cells and are pre-processed 
by a nuclear RNase III (Drosha) before export into the cytoplasm by nuclear transport 
receptor complexes. Due to limited complementarity to the target mRNA, miRNAs do not 
lead to the cleavage of mRNA with the RISC but, instead, result in translational suppression 
[2]. 
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Figure 2.1. RNA interference. Long dsRNA introduced into the cytoplasm is processed by the 
enzyme Dicer into 22-nt pieces with 2-nt single-stranded overhangs on the 3’ ends. The 
structure of synthetic siRNA mimics that of Dicer products. The siRNA guide strand is loaded 
into the RNA-induced silencing complex (RISC), and the passenger strand is cleaved by 
Argonaute-2 (AGO2). The activated RISC-guide-strand complex identifies and cleaves mRNA 
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that is complementary to the guide strand, preventing translation and thereby silencing gene 
expression. Adapted from reference[14].  Reprinted with permission from Nature. 
 
Since the discovery of RNAi, there has been an explosion of interest in using this 
technology for basic and applied research and RNAi has been one of the most promising new 
approaches for disease therapy. The list of diseases that may be treated by RNAi is extensive, 
including cancers, Parkinson’s disease [3], HIV infection[4], age-related macular 
degeneration[5], type 2 diabetes[6], obesity[7], hypercholesterolemia [8], and rheumatoid 
arthritis[9]. So far, more than 22 RNAi-based drugs have been tested in clinic (Table 1)[14], 
and many more are under exploration. 
The cancer therapeutic siRNAs have been studied for silencing target molecules that are 
crucial for tumor-host interactions and tumor resistance to chemo- or radiotherapy and the 
silencing of critical cancer-associated target proteins by siRNAs has resulted in significant 
antiproliferative and/apoptotic effects[15]. Nevertheless, most approaches to RNAi-mediated 
gene silencing for cancer therapy have been tested in vitro in the laboratory and many 
challenges for translating siRNA therapeutics to the clinic due to delivery systems still 
remain. 
The main limitations in siRNA therapeutics are instability of naked siRNA under 
physiological conditions, rapid clearance from the bloodstream, inability to cross target cell 
membranes and gain access to the intracellular environment at the clinically relevant dose. 
These drawbacks are intrinsically related to some of the unfavorable physicochemical 
properties of siRNA molecules, including negative charge, hydrophilicity, sensitivity to 
nuclease degradation and short plasma half-life of less than ten minutes[10]. Thus the 
development of siRNA therapeutics has focused on the design of a multifunctional delivery 
system that can improve siRNA stability and cancer cell specificity, involving minimal off-
target and nonspecific immune stimulatory effects.  
There has been a broad spectrum of nano-scale carriers, polymers, liposomes, conjugate 
delivery systems, cell penetrating peptides, and many others have shown unique biological 
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properties for siRNA delivery. Here, we review a variety of strategies for developing siRNA 
delivery systems for cancer therapy. 
 
Table 2.1. RNAi-based drugs in clinical trials. Adapted from reference[14]. Reprinted with 
permission from Nature. 
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2.2 Current siRNA Delivery Systems 
2.2.1 Polymeric Carriers 
Cationic polymers have been used for delivery of plasmid DNA since 1990 and, more 
recently, for siRNA delivery. The positively charged polymers interact with negatively 
charged phosphates of siRNA through electrostatic force forming the polyplexes. This 
process causes siRNA condensation and protects it from nuclease degradation. The ratio of 
the positive charges of cationic polymers to the number of phosphate groups of siRNA 
affects the size, surface charge, and structures of the polyplexes. Thus, optimization of the 
ratio, which is crucial for transfection efficiency, is required. A number of polymers, either 
synthetic or natural, such as branched or linear polyethyleneimine (PEI), poly-L-lysine 
(PLL), poly-D,L-lactide-co-glycolide(PLGA), poly(alkylcyanoacrylate), chitosan and gelatin 
have been studied. PLGA is the most extensively studied copolymer as a carrier for 
controlled release of siRNA, with lower toxicity than cationic lipids and cationic polymers. 
PLGA nano-capsules are used to stabilize siRNA and provide sustained release[16]. 
Recently, efforts have focused on modification of PLGA to get positively charged carriers to 
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increase cellular uptake. For instance, chitosan coated PLGA nanoparticles improved the 
cellular internalization of siRNA in cultured cells[17,18]. Incorporation of PEI into PLGA 
nanoparticles improved siRNA loading and activity. PEI-PLGA nanoparticles showed 100% 
siRNA loading, protected siRNA and resulted in higher gene silencing activity in cultured 
cells than PEI alone[18,19]. Intratumoral injection of PEI-PLGA microspheres of anti-VEGF 
siRNA also showed improved effect of tumor growth suppression[20]. 
Cyclodextrin polymer-based delivery system (Figure 2.2) was first used for plasmid DNA 
in 1999 and re-optimized for siRNA delivery years later[14,21–26]. Less than a decade after 
their introduction, cyclodextrin polymer-based nanoparticles entered clinical trials for siRNA 
delivery and they were the first targeting delivery systems that entered clinical trials for 
cancer[27].  Cyclodextrin polymers are polycationic oligomers (n ≈ 5), which can efficiently 
condense the nucleic acids at nitrogen/phosphorous ratios as low as 3. End-capping of the 
polymer termini with imidazole functional groups can enhance endosomal escape[28], which 
improved the delivery efficacy of siRNA[22]. Although Cyclodextrin polymers could deliver 
siRNA efficiently in vitro, they still required additional formulation components such as 
adamantane–PEG (AD–PEG) and adamantane–PEG–transferrin (AD–PEG–Tf) for 
stabilization and efficacy in vivo. Adamantane, a hydrophobic molecule, can interact with the 
cyclic core of the cyclodextrin structure to form a stable complex. PEG shielding could 
decrease protein-induced aggregation in serum. However, PEGylation also decreased cellular 
uptake and silencing efficacy. In order to recover efficacy, the protein transferrin, which can 
bind to the CD71 transferrin receptor, was conjugated to the free end of AD-PEG to improve 
efficacy[29]. The therapeutic effects of the cyclodextrin polymer-siRNA delivery system 
have been proven in several animal models: a xenograft model for Ewing’s sarcoma[22], 
targeting the oncogenic EWS–FLI1 fusion gene; a syngeneic subcutaneous mouse tumour 
model, targeting ribonucleotide reductase subunit 2[30]. In phase-I clinical trial of human 
melanoma patients, RNAi-specific gene inhibition targeting RRM2 gene was monitored by 
this delivery system, which showed its clinical potential. The low toxicity, facile 
condensation with nucleic acids, the steric stabilization through PEGylation, and the 
incorporation of a targeting ligand have made this delivery system promising in clinic. 
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Figure 2.2. Cyclodextrin polymer nanoparticles. Composition of the cyclodextrin delivery 
systems developed in reference [27]. MW: molecular weight. Adapted from reference[14]. 
Reprinted with permission from Nature. 
Dendrimers are repetitively branched molecules[31]. Dendrimers have been used as 
carriers of small molecule drugs and large biomolecules. Dendrimers with positively charged 
surface groups are used to deliver siRNA, and the precise core-shell nanostructures make it 
load siRNA by interior encapsulation, surface adsorption, or chemical conjugation. The 
biocompatibility of dendrimers depends on their structure, molecular size and surface 
charge[32]. Cytotoxicity and immunogenicity of dendrimers are related to their surface 
charge. Modifications are the main methods to improve their loading capacity and cellular 
uptake of siRNA. 
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2.2.2 Lipid-Based Carriers 
Liposomes, microemulsions, solid lipid nanoparticles, and micelles are lipid-based siRNA 
delivery systems. Liposomes are globular vesicles, which comprise the phospholipid bilayer 
and an aqueous core. The amphipathic nature of liposomes allows the incorporation of both 
hydrophilic and hydrophobic drugs. The hydrophilic head groups of phospholipid bilayers 
show affinity to hydrophilic molecules, and the fatty acyl chains of the lipid bilayer tend to 
intercalate the hydrophobic molecules into it. Liposomes are divided into two categories: 
neutral liposomes and cationic liposomes. Though neutral liposomes have achieved some 
success in delivering siRNA both in vitro and in vivo, cationic lipids remain the crucial 
components of lipid-based siRNA carriers[12]. Up to now, a number of different lipid and 
lipid-like structures and formulation methods have been developed and several features are 
particularly effective for siRNA delivery systems, such as shielding lipids, cholesterol and 
targeting ligands. 
Cationic lipids consist of three parts, a lipophilic tail group, a cationic head and a 
connecting linker. Lipophilic tail groups are usually made up of saturated or unsaturated 
alkyl chains (12-18 carbons in length) or cholesteryl groups. Cationic head groups consist of 
amidinium salt lipids, lipoamines, quaternary ammonium, and combinations of lipoamines 
and quaternary amines. Usually, esters and ethers, amides, or carbonates are used as linkers. 
The structure of the cationic head group, the carbon chain length of the tail group and the 
nature of the linker affect the transfection efficiency and the toxicity of siRNA carriers. It is 
known that lipids with small hydrophilic groups and bulky alkyl chains favor endosomal 
escape and enhance the transfection efficiency[33]. The cationic lipid condenses siRNA 
through electrostatic interaction and forms multilamellar structures. The ratio of lipid to 
siRNA can be optimized to generate a positive zeta potential for the lipoplex to help its 
interaction with the cell membrane and cellular internalization. A variety of cationic lipids 
have been investigated, and Lipofectamine 2000 is a commercialized formulation used for in 
vitro transfection.  
Lipid-based carriers have been used to deliver siRNA successfully to target sites in the 
endothelium, RES organs, and solid tumors. For example, intraperitoneal injection of 
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cationic liposomal anti-TNF-alpha gene expression prevented the development of sepsis 
induced by a subsequent lipopolysaccharide injection[33]. However the toxicogenomics of 
cationic lipids including the initiation of immune response and changes in the expression of 
non-target genes limit the use of lipid in vivo.  
Meanwhile, several studies have shown that ionizable lipids, whose charge depends on the 
pH of the surrounding environment is more efficacious[34] and less toxic than cationic lipids 
that have a net positive charge. Consequently, the focus of recent study is on the 
development of new ionizable lipids. Similarly, these lipids also include three parts: an amine 
head group, a linker group and hydrophobic tails (Figure 3a). In order to minimize toxicity, 
the pKa of an ionizable lipid needs to be optimized as low enough to become unprotonated 
during circulation but high enough to be protonated in either the early or late endosome. At 
lipid transition temperature, lipid membranes will shift from the more stable lamellar phase 
to the less stable hexagonal phase (Figure 3d), which can improve the endosome escape of 
siRNA. The lower transition temperatures lipids have, the more readily their phases shift. 
Lipids with small polar head groups and large unsaturated hydrophobic tails (Figure 3b) are 
more likely to have low transition temperatures. The structure of a lipid’s hydrophobic head 
and the linker of lipids also affect the in vivo efficacy, such as the lipid DLinDMA and DLin-
KC2-DMA (Figure 3c)[35].  Most of the ionizable lipids are two tailed species with a single 
amine. However, ionizable lipids with multitails and abundant amines have also proved 
highly efficacious[14]. 
PEG (Polyethylene glycol), a common component in liposomes, can reduce particle 
size[36,37], prevent aggregation, increase circulation time and reduce unintended uptake by 
red blood cells and macrophages[36,38]. However, it also reduces cellular uptake by target 
cells and efficacy both in vitro and in vivo. There are two strategies to reduce these negative 
effects: incorporation of acid-sensitive bonds connecting PEG to the liposome86, the use of a 
pH-sensitive modified PEG[39]. 
Cholesterol is usually included in the liposomal formulations. The increase of cholesterol 
can lower the transition temperature of liposomal membranes that contain conical-shaped 
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lipids, which induced the phase change from lamellar to hexagonal. The incorporation of 
cholesterol has been shown to enhance the release of drugs from endosome. 
 
 
Figure 2.3. Lipid structures and shapes. (a) Ionizable lipids are composed of  three sections: the 
amine head group, the linker group and the hydrophobic tails. (b) Lipids with a small head 
group and tails composed of unsaturated hydrocarbons tend to adopt a conical structure, 
whereas lipids with a large head group and saturated tails tend to adopt a cylindrical structure. 
(c) The structures of siRNA delivery lipids DLinDMA and DLin–KC2–DMA. (d) The mixing of 
  16 
cationic (orange) and anionic (blue) lipids promotes the transition from the more stable 
lamellar phase to the less stable hexagonal phase, thus aiding fusion of the liposomal and 
endosomal membranes. Adapted from reference[14]. Reprinted with permission from Nature. 
 
In order to improve the biodistribution of liposomes, targeting ligands are incorporated to 
liposomal formulation. There are two types of targeting ligands: endogenous and exogenous. 
Endogenous targeting ligands, often serum proteins, bind to the liposome during circulation 
and guide the particle to the ligand’s natural cellular target. Lipoprotein ApoE and retinol 
binding protein (RBP) are two reported endogenous targeting ligands that have achieved 
success in improving the efficacy in vivo. Meanwhile, exogenous targeting ligands have also 
been examined, such as a small molecule GalNAc and folate. GalNAc can bind to the 
asialoglycoprotein receptor on the surface of the hepatocytes, which directs the target 
delivery to the liver[40]. Folate is usually used to target rapidly dividing cancer cells[41–43].  
Although liposomes have been used for some 50 years, the number of lipids that have been 
used for creating them has been limited. Recently, by use of a high-throughput synthesis 
approach, thousands of new lipids[44–46] have been generated and screened for siRNA 
delivery. This enables the creation of promising liposomes that require lower amount of 
siRNA to achieve specific gene knockdown by three or four orders of magnitude. 
2.2.3 Conjugate Delivery Systems 
Conjugate delivery systems are developed by directly conjugating delivery materials to the 
siRNA cargo. To date, the delivery materials that have been used for conjugate delivery 
systems include cholesterol and other lipophilic molecules, polymers, peptides, antibodies, 
aptamers and small molecules. Two of the most-developed conjugate platforms are Dynamic 
PolyConjugates (DPCs) and GalNAc conjugates. 
DPCs consist of several components: siRNA cargo, a membrane-disrupting polymer, PEG 
ligand and targeting ligand (Figure 2.4).[47] The DPCs system silenced apolipoprotein B 
(ApoB) and peroxisome proliferator-activated receptor alpha (ppara) effectively in the liver 
with intravenous administration. GalNAc ligand was essential for targeting liver cells. Newer 
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generations of DPCs are more homogenous achieved by the use of new synthesis methods. 
Hydrolysable bonds are incorporated into different positions of the polymer backbone and 
side chains to reduce cytotoxicity. More stable bonds between the membrane-active polymer 
and the PEG ligand are used to extend the circulation time. In order to target other tissues 
besides liver, many types of targeting ligands have been studied, such as peptides, small 
molecules, lectins, antibodies, glycans, and nucleic acids. It is reported that two different 
conjugate delivery systems were co-injected to target the same gene in the liver and this 
strategy is currently in phase-I clinical trials.  
 
Figure 2.4. DPC conjugates. DPC materials are designed to respond to the acidic environment 
of the endosome and the reducing environment of the cytoplasm. In circulation, the membrane-
disrupting PBAVE polymer (black) is shielded by PEG. After cell uptake, the PEG chains are 
shed as the pH of the endosome lowers, exposing the polymer and causing endosomal release. In 
the cytoplasm, the disulphide bond linking the siRNA to the polymer is reduced, freeing siRNA 
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to trigger RNAi. GalNAc is included in the formulation as a targeting ligand to aid uptake by 
hepatocytes. Adapted from reference[14]. Reprinted with permission from Nature. 
 
GalNAc conjugates only include a chemically stabilized siRNA and a trivalent targeting 
ligand. In Alnylam Pharmaceuticals, three conjugates ALN-TTPsc, ALN-AT3, ALN-PCS 
are being examined for the treatment of transthyretin amyloidosis, haemophilia and 
hypercholesterolemia, respectively[48,49]. The structure of this type of conjugate is shown in 
Figure 2.5 [14]. This structure provides high affinity binding to its target ASGPR on 
hepatocytes. Study has shown that subcutaneous administration of this conjugate achieved 
better biodistribution of siNRA in the liver and higher gene silencing efficiency compared to 
intravenous administration. By changing the siRNA sequence, this conjugate can target 
different genes. 
 
 
Figure 2.5. GalNAc–siRNA conjugates. Structure of the triantennary GalNAc–siRNA conjugate 
used in several drug candidates from Alnylam Pharmaceuticals. Adapted from reference[14]. 
Reprinted with permission from Nature. 
 
Another newly developed conjugate system, oligonucleotide nanoparticles (ONPs), is 
based on nucleic acids. DNA self-assembly enabled the control over particle structure. ONPs 
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include complementary DNA fragments, chemically modified short interfering RNAs. 
Through unique overhang sequences, each particle could include six siRNA strands, each in 
certain position. The size of these nanoparticles is about 29 nm in diameter. These ONPs 
were further modified through conjugation with a targeting ligand, such as folate (Figure 
2.6). The optimized number of folate ligands was three in order to achieve significant gene 
silencing. The optimized position of these three ligands was around one side of one vertex. 
However, the ligand position did not influence the cellular uptake efficiency. Folate-ONPs 
were evaluated in vivo and have gained merit. Other delivery strategies may benefit from the 
structure-function information of this delivery system[50]. 
 
Figure 2.6 Self-assembly of oligonucleotide nanoparticles. DNA tetrahedra carrying six siRNAs 
were synthesized in a single step through hybridization of complementary strands[50]. 
Positioning of each siRNA on the surface of the tetrahedron could be controlled by using unique 
sequences in each of the siRNA 3’ overhangs. This precise synthesis method enabled the study 
of structure–function relationships , such as the effects of the number and spatial orientation of 
targeting folate ligands. Adapted from reference[14]. Reprinted with permission from Nature. 
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2.2.4 Cell Penetrating Peptide-Based Carriers 
Cell penetrating peptides (CPPs) have been utilized for the intracellular delivery of a variety 
of macromolecules, including peptides, proteins, peptide nucleic acids (PNA), plasmid 
DNA[51], and iron beads[52]. Cell penetrating peptide (CPP) mediated siRNA delivery 
systems can enter cells either through endocytic pathways or by directly crossing the cell 
membrane.  
CPP can be conjugated to siRNA through covalent cross-links, such as disulfide bonds. 
Disulfide bonds are cleaved in cells to release siRNA into the cytoplasm, where RISC 
happens. For instance, covalent conjugation of CPP penetratin or transportan to thiol-
containing siRNA via a disulfide bond shows equivalent or better gene knockdown effects 
compared to cationic liposome siRNA carriers in several mammalian cell types. Conjugation 
between siRNA and CPP affects cellular localization. For instance, conjugation of TAT-
derived oligocarbanate or TAT peptide to siRNA through chemical cross-linking enhances 
cellular uptake of siRNA and the perinuclear localization of the conjugates, whereas the non-
conjugated free TAT peptide is localized in the nucleus. Furthermore, the presence of the 
target mRNA and variations of the siRNA do not affect the subcellular localization of 
siRNA[13]. Only conjugation changed the localization of CPP [53], probably in lysosomes 
and endosomes that are localized perinuclearly.  
CPP and siRNA can also form non-covalent complexes through electrostatic interactions. 
At the right molar and charge ratios, packaging of siRNA and CPP form the positively 
charged complexes aiding in cell membrane translocation. The advantages of this 
methodology include low cost of reagents, and easy preparation of CPP/siRNA complexes. 
MPG is a peptide derived from the hydrophobic fusion peptide domain of HIV-1 gp41 
protein and the hydrophilic nuclear localization signal (NLS) of SV40 large T antigen 
(GALFLGFLGAAGSTMGAWSQPKKKRKV)[54]. siRNA can form a non-covalent 
complex with MPG. The complexes enter cells through endosome-independent pathways 
followed by entry into the nucleus. The nucleus localization requires the SV40 nuclear 
localization sequence; alterations to this sequence prevented nuclear delivery and caused the 
rapid release of siRNA into the cytoplasm[55].  
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To minimize the off-target effect of siRNA delivery, some peptides targeting specific 
cancer cells are incorporated. The evidenced ones are listed in Table 2.2[51]. 
Table 2.2. Some of the peptides evidenced to target specific tissues or cell types. Adapted 
from reference[51]. Reprinted with permission from Elsevier.  
Peptide sequence Length Targeted tissue Cellular 
target 
Reference 
TSPLNIHNGQKL 12 Human head and neck solid 
tumours 
Unknown [56] 
CGKRK 5 Tumour neovasculature Heparan 
sulfate 
[57] 
CGNKRTRGC 7a Breast carcinoma Unknown [58] 
SMSIARL 7 Prostate vasculature Unknown [59] 
FQHPSFI 7 Hepatocellular carcinoma 
cell line 
Unknown [60] 
RGD 3 Integrin receptor αvβ3 
integrin 
[61] 
NGR 3 Tumour neovasculature Amino-
peptidase N 
[62] 
VHSPNKK 7 Endothelial VCAM-1 
expressing cells 
VCAM-1 [63] 
RRPYIL 6 Adenocarcinoma cells Neurotensin 
receptor 
[64] 
EDYELMDLLAYL 12 Various carcinoma Unknown [65] 
LTVSPWY 7 Breast carcinoma erbB2 [66] 
ATWLPPR 7 Tumour neovasculature VEGF 
receptor 
[67] 
a    Excluding the cysteine residues used for peptide cyclization. 
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2.3 Uptake Pathways in Non-Viral Gene Delivery 
Most non-viral gene vectors cannot cross the plasma membrane rapidly because of their 
hydrophilic nature and large size. Endocytosis has been established to be the main 
mechanism for the internalization of non-viral vectors into the cells[68,69]. As shown in 
Figure 2.7, endocytosis can also be divided into two broad categories: phagocytosis (the 
uptake of large particles) and pinocytosis (the uptake of fluid and solutes)[70]. They differ in 
the size of the detached vesicles, in the composition of the coat (if any), and in the fate of the 
internalized particles. Multiple mechanisms for endocytosis are summarized below. 
 
Figure 2.7. Different uptake pathways in non-viral gene delivery. Adapted from [71]. Reprinted 
with permission from ASPET. 
 
• Clathrin-Mediated Endocytosis. Clathrin-mediated endocytosis (CME) is a highly 
regulated and energy-dependent process (Figure 2.8, 2.9). The ligand first binds to a 
specific cell surface receptor. As a result, the ligand-receptor complexes cluster in 
coated pits on the plasma membrane, and then, the coated pits invaginate and pinch 
off the plasma membrane, with the help of dynamin, to form intracellular clathrin 
coated vesicles (CCVs). CCVs carry concentrated receptor-ligand complexes into the 
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cells. They range in size from approximately 100 to 150 nm[72]. The clathrin coat 
then depolymerizes, resulting in early endosomes, which fuse with each other or with 
other preexisting endosomes to form late endosomes. Molecules entering cells by this 
pathway experience a drop in pH from neutral to pH 5.9 to 6 in the lumen of early 
endosomes, with a further reduction to pH 5 from late endosomes to lysosomes[73]. 
A receptor-rich region buds off to form a separate vesicle that recycles the receptors, 
and the vesicles then fuse with other late endosomes, which are eventually degraded 
in lysosomes. Therefore, a device that can enhance the release of the gene to the 
cytosol is essential. 
 
Figure 2.8. Receptor (clathrin) mediated endocytosis. Adapted from reference[71]. Reprinted 
with permission from ASPET. 
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Figure 2.9. Different cell uptake pathways involved in nanoparticle uptake into cells. Adapted 
from reference[74]. Reprinted with permission from ACS. 
• Caveolae-Mediated Endocytosis. Caveolae are small, hydrophobic membrane 
microdomains that are rich in cholesterol and glycosphingolipids[75], which are 
present in many cell types and are abundant in endothelial cells[70]. Generally, 
caveolae ranging in size from approximately 50 to 60nm are highly stable and slowly 
internalized, and caveolae uptake is a nonacidic and non-digestive route of 
internalization[76]. Caveolae-mediated endocytosis is still a promising approach 
especially if the internalization can be increased.  
• Macropinocytosis. Macropinosoms, with irregular shape and larger size, sometimes 
as large as 5 µm in diameter, have no coat and do not concentrate receptors. As a 
result, macropinocytosis is used as an efficient route for the nonselective endocytosis 
of solute macromolecules[70].  
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• Phagocytosis. Primarily specialized cells, such as macrophages, monocytes, and 
neutrophils, conduct phagocytosis in mammalian cells. Hence, phagocytosis is not 
expected to play a significant role in gene delivery. However, a phagocytosis-like 
mechanism was proposed for the uptake of large cationic lipid-DNA complexes and 
PEI polyplexes [77]. This proposed mechanism is dependent on the actin cytoskeleton 
and can explain the uptake of large particles.  
• Receptor-Mediated Endocytosis. CME is the main pathway for internalization of 
most receptors. However, other pinocytic pathways are capable of selective receptor-
mediated endocytosis events. For instance, after clathrin-mediated endocytosis was 
disrupted, the internalization of interleukin-2 into lymphocytes was partially 
inhibited, indicating that a clathrin-independent mechanism contributes to the 
efficient internalization of interleukin-2 receptors[78]. The use of receptor-mediated 
endocytosis is a promising strategy for the introduction of gene therapy agents into 
defined cell populations. For example, hepatocytes exclusively express large numbers 
of high-affinity cell surface receptors that bind to and subsequently internalize 
asialogly - coproteins[79]. Another advantage of clathrin-independent endocytosis is 
that these uptake mechanisms are relatively unaffected by lysosomal degradation. 
Thus, exploring and targeting new receptors that can be internalized by clathrin-
independent endocytosis will probably provide more efficient systems. 
Other than endocytic pathways, there are several non-endocytic pathways, such as 
microinjection, permeabilization, electroporation, fusion, and penetration. However, the first 
three techniques are highly invasive and cannot be used for in vivo gene delivery.  
2.4 Mechanisms of Endosomal Escape 
The endocytic pathway is the most widely involved mechanism to deliver nano-medicines, 
such as siRNA. However, particles entering the cells via the endocytic pathway encounter 
problems, including endosomal entrapment and subsequent enzyme digestion in the 
lysosome. These problems result in low transfection efficiency and are the main obstacles for 
most non-viral delivery systems. Thus, several approaches have been investigated to 
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facilitate the early release of therapeutic cargos from the endosomal pathway into the cytosol, 
where RISC is located. These approaches include pore formation in the endosomal 
membrane; photochemical disruption of the endosomal membrane; conformational changes 
of enhancers facilitating endosomal escape and pH-buffering effect. 
Fusogenic peptides are used in a variety of fusion systems to destabilize the endosomal 
membrane. Haemaglutinin is a peptide of the influenza virus coat, and acts as a fusogenic 
agent, which undergoes conformational changes from an anionic, hydrophilic coil at pH 7.4 
to a hydrophobic helical conformation at the acidic endosomal pH. This conformational 
change leads to fusion of the viral membrane into the cellular membrane ,[81] . 
Photochemical internalization (PCI) is another technique to disrupt the endosomal 
membrane and helps the therapeutic agents escape from the endosome. A number of 
photosensitizers such as TPPS4, TPPS2a, AIPcS2a, and dendrimer-based photosensitizer (DP) 
(dendrimerphthalocyanine (DPc)) localize primarily in the membrane of the endosomes and 
lysosomes[82,83]. After exposure to light, the photostimulation of the photosensitizer 
triggers the generation of highly reactive singlet oxygen, which destroys the 
endosomal/lysosomal membrane, whereas the contents of the organelles remain intact and 
are released to the cytosol[84]. This strategy has been applied to the delivery of therapeutic 
complexes containing CPP. However, the use of photosensitizers with siRNA and CPP may 
not be suitable for therapeutic applications because the photosensitizers may exhibit a 
different distribution of CPP/siRNA from in vitro to in vivo. 
Pore formation is another mechanism for endosomal escape. In general, pore formation is 
based on the interplay between a membrane tension that enlarges the pore and a line tension 
that closes the pore. The binding of some components such as cationic amphiphilic peptides 
(AMPs) to the lipid bilayers leads to internal stress or internal membrane tension that can be 
strong enough to form pores in the lipid membrane. Several models, for example, barrel-
stave pores or toroidal channels [85,86], have been developed to describe these events. 
The proton sponge effect, also called the pH-buffering effect, is mediated by components 
with a high buffering capacity and the flexibility to swell when protonated. Protonation 
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induces an extensive inflow of water and ions into the endosomal environment, thereby 
resulting in disruption of the endosomal membrane and release of the entrapped components. 
For example, histidine-rich molecules show a buffering effect based on protonation of the 
imidazole ring of histidine, leading to rupture of the endosomal membrane[87]. 
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Chapter 3* 
Peptide C6M3 mediated siRNA Delivery In Vitro 
Abstract 
Since its inception more than a decade ago, gene-silencing mediated by double-stranded small 
interfering RNA (siRNA) has been widely investigated as a potential therapeutic approach for a 
variety of diseases. However, the use of siRNA is hampered by its rapid degradation and poor cellular 
uptake in vitro and in vivo. Recently, peptide-based carriers have been applied to siRNA delivery, as 
an alternative to the traditional delivery systems. Here, a histidine-containing amphipathic amino acid 
pairing peptide, C6M3, which can form complexes with siRNA, was used as a new siRNA delivery 
system. This peptide exhibited a high affinity for siRNA and ability to efficiently deliver siRNA into 
the cells. The interaction of C6M3 with siRNA was investigated to determine the loading capacity of 
C6M3 at different peptide/siRNA molar ratios. A minimum C6M3/siRNA molar ratio of 10/1 was 
required to encapsulate all the free siRNA, as indicated by a gel electrophoretic assay and further 
confirmed by zeta potential analysis. The particle size distribution of the C6M3-siRNA complexes 
was studied using dynamic light scattering, which showed an intensity-based size distribution peaked 
approximately at 100 nm in RNase-free water and 220 nm in Opti-MEM C6M3 adopted a helical 
secondary structure in RNase-free water and became more so after forming complexes with siRNA. 
The interaction of siRNA with C6M3 is an entropy-driven spontaneous process, as determined by the 
results of isothermal titration calorimetry (ITC). The efficiency of cellular uptake of the siRNA 
complexes at different C6M3/siRNA molar ratios was evaluated, and the results indicated that the 
uptake efficiency was related to the molar ratio. Furthermore, a significant level of GAPDH gene 
silencing was achieved in CHO-K1 cells, with minimal cytotoxicity. 
                                                      
* This chapter is based on a manuscript. B. Chen, K. Yoo, W. Xu, R. Pan, X. Han, X. 
Ouyang, X. Qiu, P. Chen, A Histidine-containing, Amphipathic, Amino Acid Pairing Peptide 
mediated siRNA Delivery In Vitro.  
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3.1 Introduction 
The term RNA interference (RNAi) was first coined after the discovery that double-stranded 
RNAs (dsRNAs) can trigger silencing of complementary messenger RNA (mRNA) 
sequences in the nematode Caenorhabditis elegans [88]. Since the discovery of RNAi, there 
has been an explosion of interest in using this technology for basic and applied research, 
including analysis of signaling pathways and gene functions, as well as in developing a 
therapeutic method to target disease-related mRNAs in the cytoplasm of cells [88–94]. In 
spite of the high therapeutic potential of small interfering RNAs (siRNAs), their negative 
charge has limited their ability to penetrate cell membranes, and naked siRNAs are easily 
degraded by nucleases [10].  
To date, a number of materials have been used to develop siRNA delivery systems, 
including virus vectors, liposomes, lipoplexes, polymers, and peptides [11,12]. Among them, 
cell-penetrating peptides (CPPs) have been utilized for intracellular delivery of a variety of 
macromolecules, including proteins, peptide nucleic acids (PNA), and siRNAs [13]. 
CPPs can be conjugated to siRNA through covalent cross-links such as disulfide bonds. 
The disulfide bonds are cleaved in cells, releasing the siRNA into the cytoplasm, where the 
RNA-induced silencing complex (RISC) forms [13]. CPPs and siRNA can also form non-
covalent complexes through electrostatic interactions. At certain molar or charge ratios, 
siRNA and CPPs form positively charged complexes that are translocated across the plasma 
membrane. The advantages of this methodology include the low cost of the reagents and the 
easy preparation of CPP-siRNA complexes [54,55].  
CPP-siRNA complexes can enter cells either through endocytotic pathways or by directly 
crossing the cell membrane [71]. In our previous study, we reported that a new amphipathic, 
amino-acid pairing peptide, C6, formed complexes with siRNAs in a non-covalent manner 
and protected the siRNA from degradation [95]. Although its cellular uptake was highly 
efficient, we found that its gene silencing activity was not significantly high (not reported). 
Therefore, it was concluded that after entering cells, the C6-siRNA complexes were trapped 
in endosomes[95], which decreased their gene silencing efficiency. Strategies to induce the 
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membrane disruption are required. Tryptophan (W), because of its aromaticity, flat rigid 
shape, and π electronic structure, has a strong preference at the membrane interface and acts 
as an anchor to the cell membrane [96–99], thus enhances the peptide-membrane interaction. 
Histidine proves to enhance the endosomal membrane disruption through proton sponge 
effect [87,100,101]. Therefore, C6 (Ac-RLLRLLLRLWRRLLRLLR-NH2) was modified to 
C6M3 (Ac-RLWHLLWRLWRRLHRLLR-NH2), where histidine and a higher amount of 
tryptophan were incorporated. In this study, the physicochemical properties, cytotoxicity, 
cellular uptake and gene silencing efficiency of C6M3-siRNA complexes were investigated. 
3.2 Materials & Methods 
3.2.1 Materials 
Peptide C6M3 (Ac-RLWHLLWRLWRRLHRLLR-NH2, MW=2621 g/mol) was synthesized 
by CanPeptide Inc (Quebec, CA) with a purity of >95%. siRNA targeting the glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) gene and Cy3-labeled GAPDH siRNA were 
purchased from Ambion (SilencerTM GAPDH siRNA kit). The siRNA targeting sequence for 
eGFP, GCGACGUAAACGGCCACAAGU was purchased from Dharmacon. The antisense 
sequence is ACUUGUGGCCGUUUACGUCGC, and the sense sequence is 
GACGUAAACGGCCACAAGUUC. The negative control siRNA, which sets the threshold, 
is crucial for determining the transfection efficiency of an siRNA. The negative control 
siRNA used here was purchased from Ambion. Cell counting kit-8 (CCK-8) was used for 
cell viability test and was purchased from Dojindo Molecular Technologies. 
3.2.2 Methods 
3.2.2.1 Cell line 
Chinese hamster ovary cells (CHO-K1) [purchased from American Type Culture Collection 
(ATCC CCL-61)] were grown in F-12K medium (Thermo Scientific, Ontario, CA) 
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, Ontario, CA). The cells 
were incubated at 37oC in 5% CO2. 
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3.2.2.2 Preparation of siRNA complexes 
For the cell treatments, the peptide/siRNA complexes were prepared in Opti-MEM 
(Invitrogen, California, USA). For the physicochemical characterization, the complexes were 
prepared in RNase-free water. The complexes were generally incubated at room temperature 
for 20 min immediately before transfection/measurements. 
3.2.2.3 Agarose gel-shift assay 
Samples containing 300 ng of eGFP siRNA were electrophoresed on a 1.2% wt/vol agarose 
gel in 1x TBE at 55 V for 1 h. The ethidium bromide-stained siRNA was visualized on a UV 
transilluminator equipped with a camera. 
3.2.2.4 Isothermal titration calorimetry (ITC) 
The isothermal titration calorimetry experiments were conducted using a Nano-ITC 
calorimeter (TA Instruments). A 250 µM C6M3 peptide solution and a 10 µM siRNA 
solution were both prepared in RNase-free water. All of the samples were degassed in a 
degassing station (TA Instruments) prior to the experiments. RNase-free water was placed in 
the ITC reference cell. For each titration, 2 µl of the peptide in a pipette rotating at 250 rpm 
was injected into the siRNA solution in the sample cell of the calorimeter, which was 
equilibrated to 25oC, with an interval of 300 s between injections. The heat of dilution was 
measured by titrating the C6M3 solution into RNase-free water and was later subtracted from 
the sample measurement. The data were analyzed using NanoAnalyze software v.2.3.0.  
3.2.2.5 Dynamic light scattering and zeta potential 
Particle size measurements were conducted at 25oC in transparent ZEN0040-disposable 
microcuvette cells (40 µl) using a Zetasizer Nano ZS (Malvern, UK) after the samples were 
allowed to stabilize for 20 min at peptide-siRNA molar ratios of 10/1, 20/1 or 40/1 with a 
final siRNA concentration of 100 nM in RNase-free water. At molar ratio 40/1, the particle 
size of peptide-siRNA complexes was also measured after incubation for 40 min and 90 min 
respectively. After the incubation of peptide-siRNA complexes (molar ratio: 40/1) for 20 min 
at 25oC, the sample was further incubated at 37oC and the particle sizes were measured after 
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incubation for 30 min and 60 min respectively. In order to study the effect of Opti-MEM 
culture medium on the particle size, the peptide-siRNA complexes (molar ratio 40/1) were 
prepared in Opti-MEM and incubated for 20 min at 25oC following with size measurements. 
The zeta potentials of the peptide-siRNA complexes were measured using a Clear DTS1070-
zeta dip cell.  
3.2.2.6 Scanning electron microscopy (SEM) 
SEM was used to characterize the morphology of C6M3-siRNA complexes at a molar ratio 
of 20/1 with siRNA concentration of 100 nM. Right after incubation for 20 min, 40 µl 
samples were allowed to dry at room temperature over substrates. The samples were coated 
with gold (10 nm in thickness) before taking images. The SEM images were taken with a 
LEO FESEM 1530 field-emission SEM.  
3.2.2.7 Circular dichroism (CD) spectroscopy 
Spectra at 250 to 190 nm with a spectral resolution and pitch of 1 nm and scan speed of 200 
nm/min were recorded using a J-810 spectropolarimeter (Jasco, USA). Increasing amounts of 
siRNA were added to the peptide solution (30 µM), to obtain different molar ratios. The 
samples were transferred into 1-mm long quartz cells and maintained at 25oC. The spectra 
presented here are the average of three measurements. 
3.2.2.8 Cytotoxicity of peptide-siRNA complexes 
CHO-K1 cells were seeded at 5,000 cells/well in clear, flat-bottomed, 96-well plates (Costar) 
24 h before treatment. After washing the cells, the peptide-siRNA complexes or control 
samples prepared in 100 µl of Opti-MEM were added to the wells and incubated for 4 h. 
Thereafter, 50 µl of 30% serum containing medium was added, and the cytotoxicity of the 
relevant reagents was determined by the CCK-8 assay after 48 h. The reagent was added 
according to the manufacturer’s instructions and the absorbance at 570 nm was measured 
with a plate reader (BMG, FLUOstar OPTIMA, Germany). The background absorbance of 
the multiwell plates at 690 nm was determined and subtracted from the 570 nm 
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measurement. The results obtained from triplicate wells were averaged and normalized to the 
value obtained from non-treated samples. 
3.2.2.9 Cellular uptake 
CHO-K1 cells were seeded in a 24 well plate 24 h before treatment. The cells were incubated 
with C6M3-Cy3-labeled GAPDH siRNA complexes at a molar ratio of 20/1 for 4 h. 
Thereafter, the cells were washed three times with PBS and then fixed by 4% 
paraformaldehyde (PFA). The nucleus of the cell was stained by DAPI. The image showing 
the intracellular localization of Cy3-labeled siRNA was taken with a fluorescence 
microscope. 
The cellular uptake of Cy3-labeled siRNA was quantified using flow cytometry (BD 
Biosciences, BD FACSVantage SE Cell Sorter, USA). CHO-K1 cells (50,000) were 
incubated in 24-well plates for 24 h. The medium was replaced with Opti-MEM (Invitrogen) 
containing complexes or control samples with a final siRNA concentration of 100 nM. After 
incubating for 4 h, the cells were rinsed with PBS and then washed with heparin (10 U/ml). 
After washing the cells, trypsin-EDTA was added to detach them from the plate. The cells 
were re-suspended in 4% paraformaldehyde (PFA) and placed in FACS tubes for analysis. 
3.2.2.10 In vitro gene-silencing efficiency  
CHO-K1 cells were seeded at 3,5000 cells/well in 24-well plates and incubated for 24 h. 
Next, the cells were incubated with various complex formulations in Opti-MEM at 37oC for 
4 h. Then, the cells were incubated for an additional 48 h in complete culture medium. 
siRNA concentration was 100 nM. 
For qRT-PCR analysis, the total RNA was extracted from the treated cells using the SV 
Total RNA Isolation System (Promega, CA, USA). A Nanodrop (Nanodrop 
spectrophotometer ND-1000, Thermo Scientific, Ottawa, CA) was used to determine the 
RNA concentrations. The RNA samples were reverse-transcribed into cDNA using a Bio-
Rad iScript cDNA synthesis kit according to the manufacturer’s protocol. After the cDNA 
was synthesized, PCR was performed with Brilliant II fast SYBR Green QPCR Master Mix 
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(Agilent Technologies, Wilmington, DE, USA) using an Mx3005PTM real time PCR System 
(Agilent Technologies). The sequences of the primers used for the mouse GAPDH gene are 
5’-TTGCTGTTGAAGTCGCAGGAG-3’ and 5’-TGTGTCCGTCGTGGATCTGA-3’ 
(Sigma, Oakville, Ontario, Canada). Cyclophilin, a housekeeping gene, was used as an 
internal control to normalize the GAPDH gene expression. Mouse cyclophilin mRNA 
amplified using the following primers: 5’-AGGGTTTCTCCACTTCGATCTTGC-3’ and 5’-
AGATGGCACAGGAGGAAAGAGCAT-3’ (Sigma, Oakville, Ontario, CA).  
 
3.3 Results 
3.3.1 Physicochemical Characterization of siRNA Complexes 
The binding of siRNA with C6M3 was investigated using agarose gel electrophoresis. A 21-
mer siRNA that target the eGFP gene was used in this experiment. C6M3-siRNA complexes 
prepared using a series of molar ratios were investigated. As shown in Figure 3.1, lane 1, 
siRNA alone easily migrated through the gel due to its small size and negative charge. Due to 
the larger size and positive charge of the cationic C6M3-siRNA complexes, their migration 
through the gel was impeded. At a molar ratio of 10/1, the siRNA molecules were all bound 
to C6M3 because no free siRNA was detected in the agarose gel.  
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Figure 3.1. Binding ability of siRNA to C6M3 studied by agarose gel-shift assay. The formed 
C6M3-siRNA complexes, stained with ehidium bromide, were investigated by electrophoresis 
on agarose gel (1.2% wt/vol). siRNAs, targeting eGFP genes, were complexed with C6M3 at a 
series of molar ratios from 1/1 to 80/1. Lane 1 was siRNA control, and lanes 2-8 indicated 
correlated molar ratios. The amount of siRNA was 300 ng/well. 
The interactions between C6M3 and siRNA were further studied by ITC while the siRNA 
(in RNase-free water) was titrated with C6M3 at 25oC. As shown in Figure 2A, the heat 
exchange during the titration of siRNA by C6M3 was detected by the machine and output as 
raw data. By fitting the raw ITC data to a single-site model (Figure 3.2B), the 
thermodynamic parameters of the interaction were obtained and listed in Table 3.1. 
Table 3.1. Thermodynamic parameters when titrating siRNA with C6M3 in water. 
Ka (1/M) ΔH (kJ/mol)  n TΔS (kJ/mol) ΔG (kJ/mol) 
8.59⋅108   -16.12  6.97  34.87 -50.99 
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Figure 3.2. Calorimetric titration of siRNA with C6M3 at room temperature in RNasefree 
water. A) Corrected thermogram of calorimetric titration of siRNA with C6M3, B) Binding 
analysis of siRNA with C6M3 by fitting the raw data with an independent model. C6M3 
concentration was 250 µM, siRNA concentration was 10 µM. 
 
The obtained molar stoichiometry of 6.96 was very close to the theoretical value of 7, 
considering that the C6M3 peptide contains 6 positively charged arginine residues and there 
are 21 pairs of negatively charged nucleotides in the siRNA molecule. With an enthalpy of -
16.12 kJ/mol, a ΔS of 117.0 J/(mol⋅K), and an entropy of -34.87 kJ/mol, the binding was 
predominantly entropy-driven. Moreover, the Gibbs free energy calculated using the equation 
ΔG=ΔH-TΔS was -50.99 kJ/mol, indicating that the C6M3 peptide and siRNA formed 
complexes spontaneously [102,103]. 
Table 3.2 shows the detailed results of the size and charge characterization of C6M3-
siRNA formulations evaluated in this study. As shown in Table 3.2, the particle size 
decreased over the increase of molar ratios. The possible reason is that at higher molar ratios, 
the nanoparticles were more condensed [104]. The size of C6M3-siRNA complexes 
remained in the range of 70–100 nm, which indicated that the complexes most possibly 
entered cells through endocytosis [105]. At a molar ratio of 10/1, the C6M3-siRNA 
complexes have an approximately neutral zeta potential. Increasing the molar ratios, C6M3-
siRNA complexes exhibited a more positive surface charge due to the addition of more 
cationic peptides. In order to increase the affinity of C6M3-siRNA complexes with 
negatively charged cell membranes, we usually use molar ratios higher than 10/1 for the cell 
transfection experiments. 
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Table 3.2. The hydrodynamic diameter and zeta potential of the C6M3-siRNA complexes at 
different molar ratios were measured by dynamic light scattering (DLS).  
Sample Size ± SD (nm) Zeta potential ± SD (mV) 
C6M3-siRNA 10/1 97 ± 3 0.4 ± 6.17 
C6M3-siRNA 20/1 80 ± 1 23 ± 7.91 
C6M3-siRNA 40/1 72 ± 1 30.5 ± 6.50 
The siRNA concentration was fixed as 100 nM. At different molar ratios, the amount of C6M3 was 
adjusted. Results are expressed as mean ± standard deviation (n=3). 
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Figure 3.3.  (A) Size of Peptide-siRNA complexes at molar ratio 40/1 in RNase-free water at 
25oC, after incubation for 40 min and 90 min; (B) size of C6M3-siRNA complexes at molar ratio 
40/1 at 37 oC, after incubation for 30 min and 60 min; (C) size of C6M3-siRNA complexes at 
molar ratio 40/1 in Opti-MEM at 25oC, after incubation for 20 min. siRNA concentration was at 
100 nM. MR = molar ratio (peptide/siRNA). 
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Figure 3.3A shows that in RNase-free water, after incubation for 40 min at 25oC, the 
particle size of C6M3-siRNA complexes (molar ratio 40/1) slightly increased. When the 
incubation time was increased to 90 min, the particle size increased to 140 nm, possibly due 
to the aggregation of the particles. This data indicated the particle size remained almost the 
same up to 40 min and significantly increased after incubation for 90 min. Figure 3.3B shows 
that after the peptide C6M3 and siRNA formed complexes at 25oC, the particle size changed 
after incubation at 37oC for 30 min and 60 min respectively. At 25oC, C6M3-siRNA 
complexes (molar ratio 40/1) in RNase-free water displayed size distribution around 70 nm; 
at 37oC, the particle size decreased to 50 nm (30 min). Considering the C6M3-siRNA 
complexes formation process is entropy driven (ITC data), increasing the temperature leads 
to the increase of hydrophobic forces,  which may increase the compactness of the particles.  
Moreover, at  37oC , increaseing the incubation time to 60 min, the particle size remained 
almost the same as that after incubation for 30 min. At 25oC, C6M3-siRNA complexes 
(molar ratio 40/1) prepared in Opti-MEM exhibited size distribution around 220 nm (Figure 
3.3C), which was much higher than that prepared in RNase-free water. This difference is 
possibly caused by the ionic effect in the Opti-MEM.  
Figure 3.4A shows that C6M3 formed complexes with siRNA displaying a spherical shape. 
Moreover, the size distribution of C6M3-siRNA complexes was consistent with the DLS 
results. The impact of siRNA on the secondary structure of C6M3 was evaluated using CD 
spectroscopy. As shown in Figure 3.4B, C6M3 in water exhibited a maximum spectrum of 
approximately 190 nm and a minimum of approximately 208 nm, which together indicated a 
helical conformation. When a small amount of siRNA (molar ratio of 20/1) was added, a 
shift in the spectrum minimum from 207 nm to 210 nm and a second minimum spectrum of 
approximately 222 nm were observed. Adding more siRNAs to attain a molar ratio of 10/1 
increased the absolute values in spectrum minima at 208 and 222 nm, and the maximum 
around 190 nm. These results indicated an increase in the α helical secondary structure of the 
peptide occurred upon the addition of siRNA. The more siRNA was added, the more helical 
content of C6M3 secondary structure adopted. The conformational changes of the peptide 
after forming complexes with siRNA confirm that once siRNA neutralized some of the 
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positive charges of the peptide, the repulsion between these charges decreased. Therefore, it 
became much easier for the peptide to form typical α helical secondary structure that was 
reported to facilitate the cellular uptake of peptide-siRNA complexes [106]. 
 
 
Figure 3.4. (A) Morphology of C6M3-siRNA complexes at a molar ratio of 20/1, where siRNA 
concentration was 100 nM. (B) CD spectra of C6M3 alone and C6M3-siRNA at different molar 
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ratios. MR = molar ratio (peptide/siRNA). C6M3 concentration was fixed as 30 µM and C6M3-
siRNA complexes were formulated at molar ratios of 10/1 and 40/1. 
3.3.2 Cytotoxicity of C6M3-siRNA Complexes 
As shown in Figure 3.5, the viability of cells treated with C6M3-siRNA complexes was more 
than 90%. However, cells treated with Lipofectamine 2000 showed significant toxicity, with 
cell viability of 57%. These results clearly show that peptide C6M3 induced much lower 
cytotoxicity than Lipofectamine 2000. Moreover, peptide alone at corresponding 
concentrations of different molar ratios achieved >90% cell viability. 
 
Figure 3.5. Viability of CHO-K1 cells after 48 h treatment. N.T.= Non treated, 
MR=peptide/siRNA molar ratio, Lipo=Lipofectamine 2000. siNRA concentration was at 
100 nM. (n=3) 
3.3.3 Cellular Uptake of siRNA Complexes 
CHO-K1 cells were treated with the C6M3-Cy3-labeled siRNA complexes to study 
the intracellular localization and cellular uptake of siRNA. When provided in 
complexes with a peptide/siRNA molar ratio of 20/1 (Figure 3.6), the siRNA was 
localized to regions in close proximity to the nuclear membrane. The siRNAs were 
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distributed in a non-homogeneous pattern at the periphery of the nucleus, indicating 
the possibility of endocytotic delivery [107]. The efficiency of C6M3 to deliver 
siRNA into CHO-K1 cells was evaluated using fluorescence-activated cell sorting 
(FACS). As shown in Figure 3.7, the treatment of CHO-K1 cells with Cy3-labeled 
GAPDH siRNA alone achieved almost no uptake, implying that siRNA without an 
efficient carrier was not able to enter the intracellular environment. However, the 
efficiency of cellular uptake of the siRNA significantly increased with the increase in 
the C6M3 peptide/siRNA molar ratio from 10/1 to 40/1. In addition, at molar ratios of 
40/1, C6M3-Cy3-labeled siRNA complexes entered more cells than Lipofectamine 
2000-siRNA complexes, suggesting the pronounced delivery efficiency of C6M3. 
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Figure 3.6. The fluorescence microscopy image of C6M3-siRNA complexes at molar ratio 20/1 
(magnification: 40x). The red fluorescence indicated Cy3-labeled siRNA, blue fluorescence 
represented DAPI stained nuclei. The lower panel was non-treated (NT) cells, used as a control. 
siNRA concentration was at 100 nM. 
MR 20 
NT 
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Figure 3.7. Cellular uptake of Cy3-labeled siRNA. Non-treated (N.T.) sample was negative 
control; Lipo = Lipofectamine 2000, was positive control (1 ul of Lipo/well). MR = molar ratio 
(peptide/siRNA). siRNA concentration was at 100 nM. 
3.3.4 In Vitro Transfection 
The efficiency of GAPDH gene silencing by C6M3-siRNA complexes at the mRNA level 
was investigated using qRT-PCR. Lipofectamine 2000 was used as the positive control. As 
shown in Figure 3.8, the Lipofectamine 2000-siRNA complexes induced the silencing of 
GAPDH gene by 84%, and the C6M3-siRNA complexes at 40/1 achieved 69% GAPDH gene 
silencing efficiency. The significant silencing efficiency of GAPDH gene induced by C6M3-
siRNA complexes implied that the C6M3 peptide could effectively deliver bioactive siRNA 
into the cytosol and induce specific gene silencing. 
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Figure 3.8. qRT-PCR analysis of GAPDH gene in CHO-K1 cells. GAPDH siRNA concentration 
was 100 nM. NT= non-treated sample, Lipo=Lipofectamine 2000, MR= peptide/siRNA molar 
ratio.  
 
3.4 Discussion 
Here, we evaluated the ability of C6M3 to form complexes with siRNA and deliver siRNA to 
the cytosol with concomitant silencing of GAPDH expression. Based on the data of ITC and 
zeta potential, the complex formation is not only involving electrostatic force but also 
hydrophobic interaction. To investigate whether this complex formation could promote 
internalization of the peptide-siRNA complexes, FACS, a quantitative method using 
fluorescently labeled siRNA, was performed. Interestingly, with the increase of molar ratios 
from 10/1 to 40/1, the uptake efficiency of siRNA increased. The possible reasons are that at 
higher molar ratios, the peptide-siRNA complexes display higher positive charge resulting in 
stronger affinity with the negatively charged cell membrane and higher contents of 
tryptophan enhancing the peptide-membrane interaction.  
The modification of C6 has resulted in the following changes. With the same siRNA 
concentration, siRNA molecules were entirely associated with C6M3 at a molar ratio of 10/1, 
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while a very small amount of free siRNA was observed when interacting with C6 at a molar 
ratio of 10/1. This result is further confirmed by the zeta potential data. At a molar ratio of 
10/1, C6M3-siRNA complexes exhibited a slight positive surface charge (0.4 mV), while C6-
siRNA complexes obtained a negative surface charge (-13.1 mV). Moreover, C6M3-siRNA 
complexes showed smaller particle sizes (70-100 nm) than C6-siRNA complexes (170-260 
nm). The ITC data showed that both C6 and C6M3 could spontaneously form complexes 
with siRNA. However, a higher value of Gibbs free energy was observed when titrating 
siRNA with C6M3 (-50 kJ/mol) than with C6 (-40 kJ/mol), suggesting the interaction of 
siRNA and C6M3 is highly favorable. In water, C6M3 adopted helical secondary structure, 
while C6 adopted random coil structure. This conformational change may facilitate C6M3 
forming complexes with siRNA more efficiently with relatively small particle sizes due to 
the defined helical secondary structure. 
C6M3-siRNA complexes exhibited particle size ~100 nm in water and ~200 nm in Opti-
MEM. Previous studies show that particles with the size range from 50 nm to 200 nm usually 
enter cells through caveolae and clathrin mediated endocytotic pathway [74]. Fluorescence 
microscopy images of C6M3-Cy3-labeled siRNA complexes (Figure 3.6) also indicated the 
complexes entered cells possibly through endocytotic pathway [95]. Previous studies showed 
that histidine residues were incorporated in CPPs to enhance the endosomal escape of 
siRNAs [108,109]. Due to the pH drop in endosome, the imidazole ring of histidine was 
protonated. The protonation induced an extensive inflow of water and ions into the 
endosomal environment, thereby resulting in disruption of the endosomal membrane and 
release of the entrapped components [87]. Taken together, the incorporation of tryptophan 
and histidine in C^M3 sequence led to over two-fold increase of GAPDH silencing efficiency 
, compared to that of C6-siRNA complexes (25%), confirmed by the aRT-PCR analysis. 
Additionally, Effective in vivo RNAi was achieved in a human non-small lung tumor 
xenograft model through intratumor injection of the C6M3-Bcl-2 siRNA complexes (molar 
ratio: 60/1). This treatment induced marked tumor suppression, with an inhibition rate of 
55%, through suppression of antiapoptotic Bcl-2 protein in mice. [110] 
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3.5 Conclusions 
C6M3, an 18-mer-amphipathic peptide, formed complexes with siRNA exhibiting particle 
sizes from 50 nm to 220 nm. C6M3 adopted helical secondary structure in water and became 
more so upon binding to siRNA. Zeta potential and agarose gel experiments proved that 
siRNA molecules were completely associated with C6M3 at a molar ratio of 10/1. ITC data 
revealed that the stoichiometry between C6M3 and siRNA is 7/1, which is consistent with 
the theoretical value considering each peptide consists of 6 positive charge residues (R) and 
siRNA contains 21 negative charge base pairs. However, FACS results revealed that higher 
molar ratios were required to achieve better siRNA uptake efficiency. GAPDH gene 
silencing experiment and cell viability data showed that C6M3-siRNA complexes induced 
69% silencing of GAPDH gene with minimal cytotoxicity (<10%). These data demonstrate 
that C6M3 is a promising carrier for siRNA delivery and the modification strategy is useful. 
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Chapter 4† 
Design and Characterization of A New Peptide GL1 for Short 
Interfering RNA Delivery 
 
Abstract 
RNA interference holds tremendous potential as one of the most powerful therapeutic 
strategies. However, the properties of short interfering RNA (siRNA), such as hydrophilicity, 
negative charge, and instability in serum have limited its applications; therefore, significant 
efforts have been undertaken to improve its cellular uptake. Cell penetrating peptides have 
been utilized to deliver various biologically active molecules, such as proteins, liposomes, 
nanoparticles, peptide nucleic acids, and recently small interfering RNAs. Here, we introduce 
a new cell penetrating peptide GL1(Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2) to 
improve the intracellular uptake of siRNA. This peptide consists of four tryptophan residues 
that facilitated its binding with the cell membrane, five arginine residues and one lysine 
residue which are positively charged at physiological pH, which induced the formation of 
peptide-siRNA complexes and enhanced the affinity of the peptide and cell membrane. 
Moreover, GL1 adopted helical secondary structure due to the altered distribution of polar 
and nonpolar residues in the sequence.  In this study, we investigated the effect of 
peptide/siRNA molar ratio on the particle size, surface charge, secondary structure, and 
uptake efficiency. The results showed that GL1 formed stable complexes with siRNA mainly 
through electrostatic interaction and hydrophobic interaction, and the complexes displayed a 
spherical shape with the size of ~100 nm and positive surface charge. Utilizing the 
techniques of fluorescence microscopy and flow cytometry, the intracellular localization of 
                                                      
† This chapter is based on a paper. B. Chen, W. Xu, R. Pan, P. Chen. Design and 
Characterization of A New Peptide Vector for Short Interfering RNA Delivery. Journal o 
Nanobiotechnology, 2015, accepted. 
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Cy3-labeled GAPDH siRNA was visualized and the cellular uptake was quantified. It is 
worth noting that in the serum free environment, compared to Lipofectamine 2000, GL1 
achieved higher cellular uptake of siRNA (~95%); in the presence of serum, GL1 retained the 
same level of siRNA cellular uptake (~84%) as Lipofectamine 2000. In addition, the viability 
of cells treated by GL1 in all studied molar ratios was >85%, which was significantly higher 
than that treated by Lipofectamine 2000 (~70%). Taken together, the peptide GL1 
demonstrated promise as a siRNA delivery system. 
 
4.1 Introduction 
The discovery of RNA interference (RNAi) has changed the field of gene therapy. RNAi is a 
post-transcriptional gene silencing process that can specifically and potently knock down the 
expression of target genes both in vitro and in vivo [31,111]. RNAi can be induced by short 
interfering RNA (siRNA). siRNAs are double stranded RNA fragments with 21 to 23 
nucleotides that are capable of inducing the cleavage of mRNAs with the complementary 
sequence [31,111,112]. It is currently accepted that RNAi is one of the most important 
strategies for sequence-specific gene silencing in basic research and a potentially powerful 
therapeutic treatment for various human diseases [113],[114]. However, siRNA induced 
RNAi at cellular level is limited by its poor cellular uptake associated with low permeability 
of the cell membrane to RNA [115]. Thus, an effective and safe transport system to condense 
and deliver synthesized siRNA into cells is mandatory. During the last two decades, a new 
family of peptides known as cell-penetrating peptides (CPPs) were identified and thoroughly 
studied. CPPs present the ability to cross cellular membranes by a remarkably low toxic 
process and to promote the cellular internalization of biomolecules such as peptides, proteins, 
nucleic acids, peptide nucleic acids (PNA), liposomes, and nanoparticles [116–119].  
However, the efficacy of siRNA delivery mediated by CPPs remains unsatisfactory, mainly 
due to the insufficient delivery efficiency, cytotoxicity, and/or sensitivity to the medium 
[115]. 
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In order to increase the potency of such vectors, we designed a new peptide GL1. The 
following criteria were considered for the peptide design and its sequence contains: (1) 
hydrophobic residues, such as tryptophan, to facilitate membrane binding owing to its strong 
preference for the lipid membrane interfacial region [120]; (2) cationic residues, such as 
arginine and lysine, to assist the formation of peptide-siRNA complexes and peptide-
membrane interactions through electrostatic interaction and hydrogen bonding [120]; (3) 
altered distribution of the polar and nonpolar residues, to achieve better interaction with the 
cell membrane due to the formation of helical secondary structure [121]. The prevailing 
hypothesis is that the cationic peptide GL1 electrostatically complexes with the anionic 
siRNA to produce a neutral or positively charged complex that has sufficient stability to 
allow intracellular delivery of siRNA. In this study, we investigated the physicochemical 
characteristics of GL1 when interacting with siRNA and evaluated the effect of its 
physicochemical characteristics on siRNA delivery efficiency and cytotoxicity. Chinese 
hamster ovary (CHO-K1) cells are a cell line derived from the ovary of the Chinese hamster 
and often used in studies of genetics, toxicity screening, and nutrition and gene expression 
because of its rapid growth rate. Thus, CHO-K1 was used as a model system to test the 
biological responses for siRNA delivery in this study. 
 
4.2  Materials & Methods 
4.2.1  Materials 
The GL1 peptide (Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2) with a molecular 
weight of 3123.8 g/mol, was synthesized by CanPeptide Inc. (Quebec, CA) with 95% purity. 
Cy3-labeled GAPDH siRNA was purchased from Ambion (SilencerTM GAPDH siRNA kit). 
The siRNA targeting sequence for eGFP (GCGACGUAAACGGCCACAAGU) was 
purchased from Dharmacon. The sense sequence is GACGUAAACGGCCACAAGUUC and 
the antisense sequence is ACUUGUGGCCGUUUACGUCGC. The negative control siRNA 
used here was purchased from Ambion. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide, a yellow tetrazole) assay kit was purchased from Sigma-
Aldrich (Oakville, CA). 
4.2.2  Methods 
4.2.2.1 Cell Line 
Chinese hamster ovary (CHO-K1) cells were purchased from American Type Culture 
Collection (ATCC CCL-61). The cells were cultured in F-12K medium (Thermo Scientific, 
Ottawa, Canada) with 10% fetal bovine serum (FBS) (Sigma-Aldrich, Oakville, Canada). 
The cells were incubated at 37ºC in a humidified atmosphere with 5% CO2. 
4.2.2.2 Preparation of GL1 and GL1-siRNA complexes 
The preparation of GL1 and GL1-siRNA complexes followed the same procedures as 
presented in chapter 3. 
4.2.2.3 Gel Electrophoresis 
This experiment followed the same procedures as presented in chapter 3. 
4.2.2.4 Isothermal Titration Calorimetry (ITC) 
The isothermal titration calorimetry experiments were conducted using a Nano-ITC 
calorimeter (TA Instruments). A 500 µM GL1 peptide solution and a 10 µM siRNA solution 
were both prepared in RNase-free water. This experiment followed the same procedures as 
presented in chapter 3. 
4.2.2.5 Size and Zeta Potential Measurements 
Particle size measurements were done with a Zetasizer Nano ZS (Malvern, United Kingdom) 
with transparent ZEN0040 disposable microcuvette cells (40 µl) at 25°C. The GL1-siRNA 
samples were prepared as mentioned above with a siRNA concentration of 100nM. The zeta 
potentials were measured in a Clear DTS1070 zeta dip cell with the same machine. For zeta 
potential measurement in serum conditions, GL1-siRNA complexes were freshly prepared 
and diluted 1:10 with F12K+10% FBS. The complexes were incubated in a serum-
supplemented medium for 10 min before the measurement. 
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4.2.2.6 Scanning Electron Microscopy (SEM) 
This experiment followed the same procedures as presented in chapter 3. 
4.2.2.7 Circular Dichroism (CD) Spectroscopy 
This experiment followed the same procedures as presented in chapter 3. 
4.2.2.8 Fluorescence Microscopy and Fluorescence-Activated Cell Sorting (FACS) 
This experiment followed the same procedures as presented in chapter 3. Images were taken 
with an inverted fluorescence microscope (Zeiss AxioObserver Z1, CA) and analyzed using 
AxioVision software. 
The uptake of Cy3-labeled siRNA into the CHO-K1 cells was quantified with a BD 
FACSVantage SE Cell Sorter flow cytometry (BD Biosciences, United States). This 
experiment followed the same procedures as presented in chapter 3. 
4.2.2.9 In vitro gene silencing efficiency 
CHO-K1 cells were seeded at 3,5000 cells/well in 24-well plates and incubated for 24 h. 
Next, the cells were incubated with various complex formulations in Opti-MEM at 37oC for 
4 h. Then, the cells were incubated for an additional 48 h in complete culture medium with 
siRNA concentration of 50 nM. To determine the serum effect on gene silencing efficiency, 
the cells were directly incubated with various complex formulations in complete culture 
medium for 52 h and then prepared for analysis. 
For qRT-PCR analysis, the total RNA was extracted from the treated cells using the SV 
Total RNA Isolation System (Promega, CA, USA). A Nanodrop (Nanodrop 
spectrophotometer ND-1000, Thermo Scientific, Ottawa, CA) was used to determine the 
RNA concentrations. The RNA samples were reverse-transcribed into cDNA using a Bio-
Rad iScript cDNA synthesis kit according to the manufacturer’s protocol. After the cDNA 
was synthesized, PCR was performed with Brilliant II fast SYBR Green QPCR Master Mix 
(Agilent Technologies, Wilmington, DE, USA) using an Mx3005PTM real time PCR System 
(Agilent Technologies). The sequences of the primers used for the mouse GAPDH gene are 
5’-TTGCTGTTGAAGTCGCAGGAG-3’ and 5’-TGTGTCCGTCGTGGATCTGA-3’ 
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(Sigma, Oakville, Ontario, Canada). Cyclophilin, a house-keeping gene, was used as an 
internal control to normalize the GAPDH gene expression. Mouse cyclophilin mRNA 
amplified using the following primers: 5’-AGGGTTTCTCCACTTCGATCTTGC-3’ and 5’-
AGATGGCACAGGAGGAAAGAGCAT-3’ (Sigma, Oakville, Ontario, CA).  
4.2.2.10 Cytotoxicity Assay 
The cytotoxicity of peptide-siRNA complexes was determined by the MTT assay. In brief, 
cells were seeded at 5,000 cells/well in clear, flat-bottomed, 96-well plates (Costar) 24 h 
before treatment. After being washed, 100 µl of Opti-MEM that contained peptide-siRNA 
complexes at different molar ratios was added to the wells and incubated for 4 h. Thereafter, 
50 µl of 30% serum containing medium was added, and the cytoxicity of the relevant 
reagents was determined by the MTT assay after 48 h. The absorbance at 570 nm was read 
on a plate reader (FLUOstar OPTIMA, BMG, Germany). The background absorbance of the 
multiwell plates at 690 nm was determined and subtracted from the 570 nm measurement. 
The results obtained from triplicate wells were averaged and normalized to the value 
obtained from the non-treated cells. 
4.3  Statistical Analysis 
Results were expressed as mean values ± SD. Data were analyzed by two tailed T test and 
only p-values < 0.05 were considered statistically significant. 
4.4  Results & Discussion 
 
4.4.1  Effect of Peptide to siRNA Molar Ratio on Complex Formation 
The ability of GL1 to interact with siRNA was investigated by gel electrophoresis. Binding 
between peptide and siRNA prevented RNA from being stained by EtBr. As shown in Figure 
4.1, as molar ratio increased, the intensity of siRNA decreased sharply due to the formation 
of GL1-siRNA complexes. At molar ratio 10/1, the intensity of siRNA was significantly low. 
At a slightly higher molar ratio 15/1, no free siNRA was detected on the agarose gel. This 
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result indicated that the minimal molar ratio for siRNA delivery was around 10/1. This direct 
binding between cationic peptide and anionic siRNA would be initiated via electrostatic 
interactions. The formation of GL1-siRNA complexes and the thermodynamic parameters 
associated with the binding between peptide and siRNA was further investigated using 
isothermal titration calorimetry by titrating the siRNA with GL1. The heat exchange during 
the titration of siRNA by GL1 (in RNase-free water) was detected by the machine and output 
as raw data. By fitting the raw data (upper panel of Figure 4.2) to a single-site model (lower 
panel of Figure 4.2), the thermodynamic parameters during the interaction were obtained and 
listed in Table 4.1. 
 
Figure 4.1. Binding ability of siRNA to GL1 studied by agarose gel-shift assay The formed GL1-
siRNA complexes, stained with ehidium bromide, were investigated by electrophoresis on 
agarose gel (1.2% wt/vol). siRNAs, targeting eGFP genes, were complexed with GL1 at a series 
of molar ratios from 1/1 to 80/1. Lane 1 was siRNA control, and lanes 2-8 indicated correlated 
molar ratios. The amount of siRNA was 300 ng. 
  56 
 
Figure 4.2. Calorimetric titration of siRNA with GL1 at 25 oC in RNasefree water at pH 6.  (a) 
Corrected thermogram of calorimetric titration of siRNA with GL1, (b) Binding analysis of 
siRNA with GL1 by fitting the raw data with an independent model. GL1 concentration was 
500 µM and siRNA concentration was 10 µM. 
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Table 4.1.  Thermodynamic parameters when titrating siRNA with GL1 in water. 
Ka (1/M) ΔH (kJ/mol) n Kd (M) 
ΔS 
(J/(mol⋅K)) 
4.47⋅108   -18.71 7.16 2.24⋅10-7 64.56 
 
 
GL1 represents high affinity for siRNA with the dissociation constant of 2.24E-7 M. The 
obtained molar stoichiometry was 7.16, which implied that 7.16 moles GL1 could condense 1 
mole siRNA. Theoretically, 7 moles GL1 could condense 1 mole siRNA, since the GL1 
peptide contains 6 positively charged residues (Arginine and Lysine) and the siRNA 
molecule consists of 21 pairs of negatively charged nucleotides. The experimental data was 
consistent with the theoretical value. In the ITC experiment, due to the stirring throughout the 
titration process, peptide and siRNA could interact to its full extent. However, in the gel 
experiment, the peptide and siRNA solution was mixed first and then incubated for 20 min 
without further mixing. The difference in the experimental settings leads to the slight 
difference in the molar stoichiometry. With an enthalpy of -18.71 kJ/mol, ΔS of 64.56 
J/(mol⋅K), and entropy of -19.24 kJ/mol, the binding was entropy-driven, but enthalpy was 
also a major factor. Moreover, through calculation using the equation ΔG=ΔH-TΔS, ΔG was 
-37.94 kJ/mol indicating that the formation of GL1-siRNA complexes was a 
thermodynamically favored process [102,103].  
 
4.4.2 Particle Size and Zeta Potential 
Considering that particle size and zeta potential are important characteristics of delivery 
systems associated with the delivery efficiency [122], dynamic light scattering was applied to 
gain a view of the physicochemical properties of GL1-siRNA complexes. It has been 
reported that 200 nm is the approximate limit for cellular uptake by macropinocytosis and 
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nanoparticles larger than 200 nm may hinder its cellular internalization [123,124]. As shown 
in Figure 4.3a, particle sizes remained in the range of 80-100 nm, which fell in the range 
suitable for cellular uptake. Interestingly, at molar ratio 40/1, particle size slightly decreased. 
Previous studies prove that as molar/charge ratio increased, stronger electrostatic repulsion 
between complexes occurs, leading to smaller nanoparticles [104,125]. The other possible 
reason is that excess peptides formed smaller nanoparticles, thus decreased the average size. 
It is generally accepted that nanoparticles with positive surface charge induce uptake via 
electrostatic interaction with the anionic cell membranes [126]. Figure 4.3b shows that at 
molar ratio 20/1 and 40/1, nanoparticles displayed positive surface charge and the absolute 
values increased at higher molar ratio due to the addition of more cationic peptides. This 
positive surface charge allows interaction of GL1-siRNA complexes with the polyanionic 
glycosaminoglycans on the cell surface [127]. However, in serum-containing media, GL1-
siRNA complexes exhibited a negative surface charge, indicating that serum proteins 
interacted with the outer layer of the complex and induced a negative surface charge. This 
result suggests that in serum conditions the uptake of GL1-siRNA complexes may be 
mediated by scavenger receptors, which were involved in the cellular uptake of negatively 
charged macromolecules [128]. 
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Figure 4.3. (a) The hydrodynamic diameter and (b) zeta potential of the GL1-siRNA complexes 
prepared in RNase free water at different molar ratios were measured by dynamic light 
scattering (DLS); (c) zeta potential of the GL1-siRNA complexes in serum-supplemented F12K 
media. The siRNA concentration was fixed at 100 nM. At different molar ratios, the amount of 
GL1 was adjusted. Results are expressed as mean ±  standard deviation (n=3).  
 
4.4.3 Morphology and Secondary Structure 
Moreover, Figure 4.4a shows the morphology of the GL1-siRNA complexes formed at molar 
ratio 40/1 observed under SEM. The SEM image shows that GL1 and siRNA form spherical 
nanoparticles with the size less than 100 nm. As shown in Figure 4.4b, The CD-spectrum of 
GL1 is characterized by a maximum at 190 nm, a minimum at 207 nm, and a slight shoulder 
at 220 nm which implies that GL1 adopts α-helical structure. Upon adding siRNA to retain 
the peptide/siNRA molar ratio 10/1, GL1 CD-spectrum displayed a minimum at 210 nm, a 
maximum at 190 nm, a slight shoulder at 220 nm, and the absolute values of the minimum 
and maximum increased, which reveals that GL1 adopts a higher content of α-helical 
structure. Adding more siRNA to retain the peptide/siRNA molar ratio at 5/1, GL1 
represented a similar CD-spectrum and the absolute values of the minimum and maximum 
further increased. Similar phenomena have been reported for other CPPs [129] and this 
conformational change is due to the presence of anionic component, siRNA, which can 
screen the positive charge of arginine residues in one face of the helical structure, thus, 
forming a stable helical structure. This stable helical structure facilitates better interaction 
with cell membranes and enhances cellular internalization [106]. 
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Figure 4.4. (a) SEM image of GL1-siRNA complexes at molar ratio 40/1, siRNA concentration 
was 100 nM. (b) CD spectra of GL1 alone and GL1-siRNA at different molar ratios. GL1 
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concentration was fixed at 30 µM and GL1-siRNA complexes were formulated at molar ratios 
of 5/1 and 10/1. 
 
4.4.4 Cellular Uptake and Localization of siRNA Complexes 
The cellular localization of siRNA was shown in Figure 4.5a. The siRNAs were localized in 
cytosol and to regions in close proximity to the nuclear membrane and were distributed in a 
non-homogeneous pattern at the periphery of the nucleus. Previous studies demonstrated that 
localization of siRNA [130], Dicer [131], and RNAi activity [132] was restricted to the 
cytoplasm and siRNA entry into living cells was localized to perinuclear regions [53]. Our 
data indicating that siRNA localization was perinuclear (Figure 4.5a, upper panel) was in 
consonance with the previous studies. 
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Figure 4.5. (a) Fluorescence microscope image of GL1-siRNA complexes at molar ratio 40/1 
(magnification: 40x). The red fluorescence indicated Cy3 labeled siRNA, blue fluorescence 
represented DAPI stained nuclei. The lower panel was non-treated cells, used as a control. (b) 
FACS results of cellular uptake of siRNA. * P value<0.05, in a serum free environment, the 
uptake of siRNA at molar ratios of 20/1 and 40/1 is significantly different from that after Lipo 
treatment. ** P value<0.05, in a serum environment, the uptake of siRNA at a molar ratio of 
20/1 is significant from that at a molar ratio of 40/1 and after Lipo treatment. (c) Relative 
fluorescent intensities at different treatment conditions. * P value <0.05, the fluorescence 
intensity at molar ratios of 20/1 and 40/1 with or without serum is significantly different from 
that after the other treatments. Non-treated sample was negative control; Lipo-siRNA 
complexes were positive control. Cy3 labeled GAPDH siRNA was used here. siRNA 
concentration was 100 nM in both experiments. (N.T.= Non-treated, MR=peptide/siRNA molar 
ratio, Lipo=Lipofectamine 2000). Results are expressed as mean ±  standard deviation (n=3).  
 
siRNA cellular uptake was quantified by FACS. As shown in Figure 4.5b, c, either with or 
without the presence of serum, siRNA alone represented almost no uptake in CHO-K1 cells, 
which also confirmed the limitation of siRNA alone in cellular uptake. Without the presence 
of serum, peptide GL1 achieved 95% uptake of siRNA at molar ratio 20/1 and 40/1, which is 
higher than Lipofectamine 2000 (Lipo, 87%), one of the most efficient and commercially 
available transfection reagents. Due to the serum effect, the uptake of siRNA decreased to 
75% (molar ratio 20/1) and 84% (molar ratio 40/1). However, at molar ratio 40/1, GL1 still 
achieved the same level of uptake as Lipo with the presence of serum. However, with or 
without serum, GL1-siRNA treated cells exhibited higher fluorescence intensity than Lipo 
and fluorescence intensity increased with the peptide/siRNA molar ratio. This result 
indicated that peptide GL1 could effectively protect siRNA and efficiently deliver siRNA to 
cells even in the presence of serum.  
4.4.5 Gene Silencing Efficiency In Vitro 
With or without serum, the GAPDH gene silencing efficiency induced by GL1-siRNA 
complexes (MR 40/1) at the mRNA level was investigated using qRT-PCR. Lipofectamine 
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2000 was used as a positive control. As shown in Figure 4.6, GL1-siRNA complexes at a 
molar ratio of 40/1 achieved 58% and 47% gene silencing efficiency with and without serum 
respectively. This result indicated that GL1 could efficiently deliver siRNA to cells and 
induced the specific gene silencing. With serum, gene silencing efficiency of GL1-siRNA 
complexes decreased compared to that without serum, respectively. This trend was consistent 
with the cellular uptake result. The Lipofectamine 2000-siRNA complexes induced 80% and 
74% GAPDH gene silencing with and without serum. The possible reason that GL1-siRNA 
complexes did not achieve similar gene silencing efficiency was that the complexes were 
retained inside endosomes following endocytosis [133]. 
 
Figure 4.6. Gene silencing efficiency in vitro. Silencing of GAPDH gene in CHO-K1 cells was 
evaluated by quantitative real time polymerase chain reaction (qRT-PCR). GAPDH siRNA 
concentration was 50 nM. Lipo was the positive control, and scrambled siRNA was used as the 
negative control. Results are expressed as mean ±  standard deviation (n = 3). * P value<0.05, 
the gene silencing efficiency at a molar ratio of 40/1 in a serum free environment is significantly 
different from the other treatments.  
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4.4.6 Cellular Toxicity 
For a CPP to be a functional vector, it must achieve high uptake efficiency and exhibit low 
levels of cytotoxicity. It is well documented that the molar ratio of the positive vector to 
negative nucleic acid cargo affects toxicity and higher molar ratios may cause higher toxicity 
[134]. As shown in Figure 4.7, siRNA alone was not toxic. At molar ratio 10/1, GL1-siRNA 
complexes and GL1 alone did not cause toxicity. At molar ratio ≥ 20/1, viability of cells 
treated either with GL1-siRNA complexes or GL1 alone had a slight drop owing to relatively 
higher surface charge, but it was still above 85%. Moreover, Lipo alone and Lipo-siRNA 
complexes achieved lower cell viability ~70%. Thus, peptide GL1 showed attractive 
characteristics with regards to the criteria of cytotoxicity. 
 
Figure 4.7. Cell viability results of CHO-K1 cells treated with naked Lipofectamine 2000 or 
GL1, and the complexes with siRNA (50 nM) at different molar ratios. (N.T.= Non-treated, 
MR=peptide/siRNA molar ratio, Lipo=Lipofectamine 2000). Results are expressed as mean ±  
standard deviation (n=3). * P value < 0.05, the cell viability after GL1 treatment is statistically 
significant than that after Lipo treatment. 
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Here, an amphipathic, cationic peptide GL1 was designed and investigated. Structurally, 
GL1 has dispersed cationic amino acids along the sequence, which differs from the arginine 
rich peptide R9, R9-hLF, and Tat [135]. The peptide MPG and MPG-like peptides consist of 
a hydrophobic domain and a hydrophilic domain which contributes to their amphipathic 
property [136,137]; while PF6 and PF14 incorporated a stearyl moiety in their sequences to 
improve amphiphilicity. However, peptide GL1 has hydrophilic and hydrophobic amino 
acids dispersed along the sequence, which leads to its amphipathity and helical secondary 
structure. Another significant difference of GL1 from the peptides mentioned above is that 
GL1 utilizes four tryptophan amino acids distributed along the sequence to enhance cellular 
uptake of GL1-siRNA complexes via strong peptide-membrane interaction. Gel 
electrophoresis results show that GL1 can form complexes with siRNA and encapsulate all 
the free siRNA at molar ratio 15/1. However, hLF, R9, R9-hLF, Tat, TP10, PF6, and PF14 
require much higher molar ratio, near 50/1 to encapsulate all the free siRNA [135]. The ITC 
data further proved that GL1 had a strong affinity with siRNA (Kd = 2.24E-7 M) and the 
interaction of GL1 with siRNA was thermodynamically favored (ΔG = -37.94 kJ/mol). 
Additionally, a similar value of Gibbs free energy was reported in our previous study of an 
amino acid pairing peptide C6 [95]. CADY, a 20-residue secondary amphipathic peptide also 
encapsulated all the siRNA at molar ratio 15/1 and adopted helical secondary structure. 
Compared to GL1, CADY displayed even stronger binding affinity with siRNA (Kd: 0.152E-
7 M) [138]. Interestingly, CADY enters cells not through the endosomal pathway but GL1 
does, which may lead to the difference in the efficiency of intracellular release of siRNA.  
The size of GL1-siRNA complexes slightly decreased from 100 nm to 80 nm when 
increasing the molar ratio from 20/1 to 40/1 possibly due to stronger electrostatic repulsion at 
higher molar ratio. Moreover, GL1-siRNA complexes displayed positive surface charge at a 
molar ratio of 20/1 (~ 21 mV). At a molar ratio of 40/1, due to the addition of more cationic 
peptide, GL1-siRNA complexes’ surface charge increased to 27 mV. Interestingly, GL1 
adopted a higher content of helical structure upon interaction with siRNA, possibly due to the 
decrease of the charge repulsion between cationic amino acids after partial positive charge 
was neutralized by anionic siRNA. The positive surface charge and secondary structure 
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change suggest that GL1 and siRNA form stable complexes mainly through the 
intermolecular binding and electrostatic interaction, which was consistent with some reported 
CPPs [139]. These favourable physicochemical characteristics lead to the significant cellular 
uptake of Cy3-labeled siRNA (95%), which is higher than Lipo (87%) in a serum free 
environment. In the presence of serum, GL1-siRNA complexes exhibited negative charge. 
This is possibly because excess anionic serum protein neutralizes the positive surface charge 
of GL1-siRNA complexes and displays negative charge. Due to the serum effect, cellular 
uptake of GL1-siRNA complexes dropped to 85%, which is still comparable to Lipo. 
Moreover, GL1-siRNA complexes induced 49% or 40% GAPDH gene silencing with serum 
or without serum respectively, with minimal cytotoxicity. Taken together, our experimental 
data strongly supported our hypothesis that the cationic peptide GL1 electrostatically 
complexes with the anionic siRNA to produce a positively charged complex that has 
sufficient stability to allow efficient intracellular delivery of siRNA and induce specific gene 
silencing efficiency. Note that GL1 delivered higher amount of siRNA to cells than Lipo but 
induced lower gene silencing efficiency than Lipo, possibly due to insufficient endosomal 
release of siRNA. Further modifications of GL1 to enhance endosomal release are required. 
4.5  Conclusions 
 
In this study, we have investigated the physicochemical characteristics of the peptide GL1, 
and evaluated its siRNA delivery efficiency and cellular toxicity on the CHO-K1 cell line. 
The major conclusions include the following: GL1 could form complexes with siRNA cargo 
at molar ratio ~10/1 mainly via electrostatic interaction and hydrophobic interaction; GL1 
could spontaneously condense siRNA to form spherical particles with sizes on the nanoscale 
(80-100 nm); GL1 adopted α-helical secondary structure and became more so upon 
interaction with siRNA molecules to form stable complexes; at molar ratio 40/1, GL1 
achieved higher cellular uptake of Cy3-labeled siRNA (95%) than Lipofectamine 2000 in 
serum free environment and retained the same level of uptake as Lipofectamine 2000 (84%) 
with the presence of serum; in all the studied molar ratios, GL1 achieved higher cellular 
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viability (>85%) compared to Lipofectamine 2000 (~70%). Therefore, GL1 demonstrated the 
potential for future applications as a vector for siRNA delivery. 
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Chapter 5‡ 
Peptide GL1 mediated siRNA Delivery in Multicellular Tumor 
Spheroids and its Therapeutic Effects In Vivo 
 
Abstract 
siRNAs have shown promise in silencing targeting gene expression in vitro, but this 
technique has not translated to the clinic for gene therapy. This is partly due to the difference 
in cell behavior in monolayer culture and in the three-dimensional culture, e.g., tumors, 
where the penetration and distribution of siRNAs are limited. The multicellular tumor 
spheroids (MCTS), an in vitro model representing a solid tumor, have been utilized as an 
improved model for evaluating siRNA carriers. We have previously reported that the peptide 
GL1 achieves significant siRNA delivery efficiency in monolayer culture. Therefore, we 
aimed to confirm whether GL1 could achieve similar efficacy as a siRNA delivery system in 
MCTS and in vivo. Here, we established the MCTS of Chinese hamster ovary cells and 
evaluated the penetration, efficacy and cytotoxicity of siRNAs delivered by the peptide GL1. 
The results showed that GL1 could efficiently deliver siRNAs to the MCTS and induced 50% 
GAPDH gene silencing efficiency with minimal cytotoxicity (<10%). The intratumoral 
injection of the GL1-Bcl-2 siRNA complexes in a mouse xenograft model induced a 
pronounced tumor growth inhibition rate (52.6%) through suppression of the antiapoptotic 
Bcl-2 protein. These data demonstrated the potential of GL1 as a siRNA carrier both in vitro 
and in vivo. 
 
                                                      
‡ This chapter is based on a manuscript. B. Chen, Y. Wu, W. Xu, Y. Yuan, P. Chen. GL1 
Peptide mediated siRNA Delivery in Multicellular Tumor Spheroids and Therapeutic Effects 
In Vivo. Prepared submission to the Journal of Nanomedicine. 
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5.1  Introduction 
RNA interference (RNAi) has been accepted as a general endogenous mechanism in many 
organisms to efficiently silence the expression of specific genes through the introduction of 
synthetic small interfering RNA (siRNA), whose sequence is complementary to the 
endogenous mRNA. [140] Theoretically, RNAi can be used to silence nearly any gene in the 
body through the appropriate design of siRNA, which broadens its therapeutic potential as 
compared to typical small-molecule drugs [111]. However, the nature of naked siRNA, such 
as large molecular weight, negative charge, and being prone to nuclease degradation have 
hindered the efficacy of siRNA therapeutics [141,142]. Thus, the development of safe and 
effective delivery systems to deliver siRNAs to the target tissues is critical.  
Two common strategies for targeted delivery are: 1) active targeting, involving attachment 
of targeting moieties to the surface of carriers, such as antibodies [143]; and 2) passive 
targeting, based on the enhanced permeability and retention (EPR) effect (such as tumors, 
which have leaky blood vessels). The EPR effect involves two major components, first 
altered bio-distribution, where the nano-sized particles show differential accumulation in the 
tumor tissues reaching higher concentration than that in the plasma or other organs. The other 
aspect of the EPR effect is increased plasma half-life. Nano-sized particles exceed the limit 
of renal excretion threshold and escape renal clearance due to their relatively large sizes.  
The investigation of carriers for siRNA delivery begins with in vitro testing. Such testing 
of delivery methods against target cells is generally performed in monolayer culture, multi-
well plate-based cell culture formats [144]. However, due to the lack of appropriate 
physiological barriers presented in monolayer culture, the results gained from monolayer 
culture platforms often differ from the in vivo. Therefore, an in vitro model that is more 
physiological than monolayer culture is required for better prediction of siRNA delivery 
efficacy.  
Platforms such as scaffolds, microfluidics, and hydrogels can produce 3D cell culture 
models for testing of gene/drug delivery and toxicity [145]. Spheroids are micro-scale, 
spherical cell clusters formed by self-assembly and also one of the most common and 
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versatile methods of culturing cells in 3D. The following features of spheroids make them a 
more physiological platform for siRNA delivery testing: 1) spheroids mimic the multicellular 
arrangement and extracellular matrix deposition that are found in vivo but absent in 
monolayer culture; 2) spheroids display sizeable cell-cell interactions such as tight junctions 
that are comparable to those in in vivo tissues; 3) as in vivo tissues, spheroids show the 
diffusional limits to mass transport of nanoparticles, nutrients and other factors; 4) due to 
nutrient and oxygen transport limitations, spheroids with radii of 200 µm and larger can 
develop zones of proliferating cells on the outer layers of the spheroids and quiescent cells on 
the inside, while significantly larger spheroids can also develop central necrosis present in 
many cancers. [146] Taken together, spheroids provide an improved model for testing siRNA 
delivery compared to conventional cell culture but the challenge is how to form and maintain 
spheroids of uniform size. A variety of methods for spheroid generation were reviewed in 
detail previously [146]. A very recently developed method to form spheroids utilizing the 
hanging drop method has attracted researchers’ attention because of its simplicity, 
reproducibility, stability, and high throughput [147–149].  
Previously, we have shown that our peptide GL1 demonstrated a strong potential as a 
siRNA delivery system in Chinese hamster ovary (CHO-K1) cells in monolayer culture. In 
order to further confirm its potential, we developed the CHO-K1 spheroids using the hanging 
drop method and evaluated the GAPDH gene silencing efficiency and cytotoxicity induced 
by GL1-siRNA complexes in the spheroid model. Moreover, the therapeutic efficacy of Bcl-
2 siRNA delivered by GL1 peptide was evaluated in an animal xenograft model. The results 
elucidated the promise of GL1 as a safe and efficient siRNA delivery system both in vitro 
and in vivo. 
 
5.2  Materials & Methods 
5.2.1  Materials 
The GL1 peptide (Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2) with a molecular 
weight of 3123.8 g/mol, was synthesized by CanPeptide Inc. (Quebec, CA) with 95% purity. 
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Cy3-labeled GAPDH siRNA and GAPDH siRNA were purchased from Ambion 
(SilencerTM GAPDH siRNA kit). The negative control siRNA used here was purchased 
from Ambion. The WST-1 cell proliferation assay kit was purchased from Cayman 
Chemical. 
 
5.2.2  Methods 
5.2.2.1 Cell Culture 
The culture of Chinese hamster ovary (CHO-K1) cells in this chapter followed the same 
procedures as presented in chapter 3.  
5.2.2.2 Preparation of GL1 and GL1-siRNA complexes 
The preparation of Gl1-siRNA complexes followed the same procedures as presented in 
chapter 3.  
5.2.2.3 Generation of Tumor Spheroids from CHO-K1 
When the confluence of CHO-K1 cells was greater than 85%, the cells were detached with 
trypsin/EDTA and counted using a haemocytometer. Dead cells were excluded from 
counting using 75% (v/v) trypan blue stain exclusion. Cells were seeded in F12-K medium 
supplemented with 10% (v/v) FBS at desired cell density (total volume 45 µl/well), in a 96-
well hanging drop plate (3D Biomatrix). Cells were incubated at 37ºC in a humidified 
atmosphere with 5% CO2.  
5.2.2.4 Light Microscopy 
Morphology of CHO-K1 spheroids was observed by light microscopy. The diameter of the 
spheroids at different seeding densities was measured under a light microscope on day 2, 4, 
6, and 9. The measurement was done using 8 spheroids at each cell density from each time 
point. 
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5.2.2.5 Scanning Electron Microscopy (SEM) 
CHO-K1 cells were seeded at 10,000cells/well in a 96-well hanging drop plate (3D 
Biomatrix) and incubated at 37ºC in a humidified atmosphere with 5% CO2. After incubation 
of 72 h, cells formed a spheroid in each well. The spheroids were transferred to a round-
bottom clear standard 96-well plate. The culture medium was then discarded and PBS was 
added to wash the spheroids twice. After discarding the PBS, 80 µl of 4% Glutaraldehyde 
(v/v, dissolving in PBS) was added to each well and the sample was incubated at 4ºC 
overnight. The next day, the solution was discarded and 80 µl PBS was added to wash the 
sample twice. The spheroids were then placed on a silicon wafer and dehydrated through a 
series of Ethanol solution at concentrations of 50%, 75%, 90%, and 95%. Lastly, the 
spheroids were allowed to air dry at room temperature. Before imaging, samples were coated 
with 10 nm-thick gold to achieve better conductivity. Finally, the samples were imaged under 
a LEO FESEM 1530 field-emission SEM at 5 kV. 
5.2.2.6 Confocal Laser Scanning Microscopy 
CHO-K1 cells were seeded at 50cells/well in a 96-well hanging drop plate (3D Biomatrix) 
and incubated at 37ºC in a humidified atmosphere with 5% CO2. After incubation of six days, 
cells formed a spheroid in each well. After taking out 5 µl of culture medium from each well, 
10 µl of Opti-MEM that contained GL1-Cy3 labeled- siRNA complexes at molar ratio 60/1 
was added to the wells and incubated for 24h and 48h respectively. Thereafter the spheroids 
were transferred to a chamber. The culture medium was discarded and the spheroids were 
washed twice with PBS. Then the spheroids were fixed with 4% Paraformaldehyde (PFA) 
and incubated for 30 min at 37ºC. The PFA was removed and the spheroids were washed 
with PBS twice; DAPI was added at the end to stain the nuclei of cells. Then images were 
taken with Olympus Upright BX51 confocal microscope. 
LIVE/DEAD Viability/Cytotoxicity Kit (calcein AM and ethidium homodimer (EthD-1), 
Invitrogen) was used to visualize the structure of CHO-K1 cellular spheroids. Calcein AM is 
a cell permeant dye used to stain live cells. In live cells, the nonfluorescent calcein AM is 
converted to a green-fluorescent calcein after acetoxymethyl ester hydrolysis by intracellular 
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esterases. EthD-1 was used to identify dead/dying cells as it exclusively enters cells with 
disrupted cell membrane to bind DNA and emit red fluorescence. CHO-K1 cells were seeded 
at 10000cells/well in a 96-well hanging drop plate (3D Biomatrix) and incubated at 37ºC in a 
humidified atmosphere with 5% CO2. After incubation of six days, the LIVE/DEAD 
Viability/Cytotoxicity Kit was applied per manufacturer’s instruction. Thereafter, cell 
spheroids were fixed following the procedure mentioned above. Images were taken with 
Olympus Upright BX51 confocal microscope. 
5.2.2.7 Cytotoxicity 
The cytotoxicity of peptide-siRNA complexes was determined by the WST-1 assay. In brief, 
cells were seeded at 10,000 cells/well in 96-well hanging drop plates (3D Biomatrix) 72 h 
before treatment. After taking out 5 µl of culture medium from each well, 10 µl of Opti-
MEM that contained samples was added to the wells and incubated for 72 h. Thereafter cell 
spheroids were transferred to a clear, round bottom standard 96-well plate (Costar) and the 
cytotoxicity of each treatment was determined by the WST-1 assay. The assay is based on the 
enzymatic cleavage of the tertrazolium salt WST-1 to formazan by cellular mitochondrial 
dehydrogenases in viable cells. The absorbance at 450 nm was detected with a plate reader 
(FLUOstar OPTIMA, BMG, Germany). Each treatment included 6 replicates and the results 
were averaged and normalized to the non-treated group. 
5.2.2.8 In Vitro Gene Silencing Efficiency 
The GAPDH gene silencing efficiency of peptide-siRNA complexes was determined by 
qRT-PCR. Briefly, cells were seeded at 10,000 cells/well in 96-well hanging drop plates (3D 
Biomatrix) 72 h before treatment. After taking out 5 µl of culture medium from each well, 10 
µl of Opti-MEM that contained samples was added to the wells and incubated for 72 h. Each 
treatment had five replicates. Thereafter cell spheroids with the same treatment were 
transferred to an 1.5 ml Eppendorf tube and centrifuged at 200 rcf for 5 min. The supernatant 
was removed and the pellet was washed with PBS twice. Then Trizol reagents were added 
for RNA extraction, followed by cDNA synthesis and PCR.  
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5.2.2.9 Human Non-small Lung Cancer Xenograft Tumor Model and Tumor Suppression 
Study§  
Six-week-old male BALB/c nude mice were obtained from B&K Universal Group Limited 
(Shanghai, China). The mice were maintained under a 12-h light/dark cycle at 25°C with a 
humidity of 60±10%. The non-small-cell lung carcinoma-derived A549 cells were obtained 
from American Type Culture Collection (ATCC) and cultured in Dulbecco’s Modified 
Eagle’s Media-high glucose (DMEM) (Invitrogen) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) and 1% antibiotics (streptomycin + penicillin). The nude mouse 
animal model was established by subcutaneous inoculation of 5×106 A549 cells in the right 
axilla.  
When the tumor volume reached 100-200 mm3, the mice were randomly divided into five 
groups: model group, saline group, GL1 group, Bcl-2 siRNA group, GL1-Bcl-2 siRNA group 
and each group had 8 mice. The drugs were applied through intratumoral injection and low-
dose multi-point injections. The treatments, a dose of 4 µg of siRNA per mouse, were given 
every 3 days for a total of nine treatments. The mice in the saline group were injected with 20 
µl of saline and those in the GL1 group were given the same concentration of GL1 as the 
mice in the GL1-siRNA group. The body weights of the mice and the tumor diameters were 
measured daily. The estimated tumor volume was calculated using the formula: tumor 
volume = 0.5 × (width)2 × length. The mice were sacrificed on the 27th day of treatment. The 
procedures and care administered to the animals have obtained the approval of the 
institutional ethics committee, under a permit of animal use (Approval ID: (2012) 005) in 
No.3 People’s Hospital affiliated with Shanghai Jiao Tong University School of Medicine, in 
compliance with the Experimental Animal Regulation by the National Science and 
Technology Commission, China. Tumors were weighed after they were dissected from the 
mice.  
                                                      
§ This experiments were designed by us and conducted in NO.3 People’s Hospital affiliated 
to Shanghai Jao Tong University School of Medicine 
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5.2.2.10 Western Blot** 
A total protein extraction kit (Kangchen Biotechnology, Shanghai, China) was utilized to 
extract protein according to the manufacturer’s instructions. The total protein was stored at -
20°C until use. The antibodies used included Bcl-2 rabbit polyclonal IgG (Santa Cruz 
Biotechnology, Dallas, USA), horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG 
(Kangchen Biotechnology, Shanghai, China) and goat antiglyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (Kangchen Biotechnology, Shanghai, China). Protein samples 
were separated by 12% SDS-PAGE gels and then transferred to nitrocellulose (NC) 
membranes. After blocking with blocking buffer for 2h, the membranes were incubated with 
polyclonal rabbit anti-Bcl-2 (1:1000, overnight at 4°C). HRP-goat anti-rabbit IgG (1:2000, 2 
h) conjugate was used as a secondary antibody. The bound secondary antibody was detected 
by enhanced chemiluminescence (Pierce Biotechnology, Rockford, USA). The housekeeping 
gene, GAPDH, was used as an internal standard. 
5.3 Statistical Analysis 
Results were expressed as mean values ± SD. Statistical significance was determined by a 
two-tailed t test. Differences were considered significant if p＜0.05. 
5.4 Results and Discussion 
5.4.1 Morphologic Characterization of CHO-K1 Spheroids 
The CHO-K1 spheroids were generated using the hanging-drop method. Cells slowly 
aggregate in the bottom center of the hanging droplet, and eventually form into a tight 
spheroid. Figure 5.1a shows the formation of spherical, and compact CHO-K1 spheroids. At 
a higher cell seeding density with the same time point (day 5), the formed cellular spheroid 
was more densely packed at the central core region (Figure 5.1c). The diameter of CHO-K1 
multicellular spheroids with various seeding densities after incubation of 5 days was 
measured and the result suggested that at a higher cell seeding density, the spheroids were 
                                                      
** This experiment was designed by us and conducted in NO.3 People’s Hospital affiliated to 
Shanghai Jao Tong University School of Medicine 
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more condensed leading to a smaller diameter  (Figure 5.1b). Under light microscope, the 
spheroid appeared as a multilayer cell assembly (Figure 5.1c). Under scanning electron 
microscope, as shown in Figure 5.2a, in the intact spheroid, cells interconnect with one 
another forming a 3D spherical aggregate and individual cells were not distinguishable; at a 
higher magnification (Figure 5.2b), these cells held together through extracellular matrix 
throughout the spheroids. Additionally, the spheroids were resistant to physical transfer and 
gentle agitation but sensitive to enzyme digestion that could separate the spheroids into 
individual cells. A similar phenomenon was previously reported [150]. However, in 
monolayer culture (Figure 5.2c), cells were grown in flat monolayer and fused together 
through supporting connective structures. 
 
Figure 5.1. Optical characterization of CHO-K1 cellular spheroids. (a) Optical imaging (scale 
bars: 1000 µm) of CHO-K1 spheroids with seeding density of 1500 cells/well at different time 
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points. (b) Diameters of CHO-K1 cellular spheroids with seeding densities of 300 cells/well, 700 
cells/well, 1500 cells/well, 5000 cells/well, 10000 cells/well at day 5. (c) Optical image of CHO-K1 
spheroids with seeding density of 200 cells/well and 2500 cells/well at day 5 (scale bars: 400 µm). 
 
 
Figure 5.2. Morphology of MCTS of CHO-K1 cells. (a) Under SEM, the structure appeared to 
be compact and the cells were closely integrated into the solid structure in which individual cells 
were indistinguishable from each other (scale bar: 20 µm). (b) Single cells within the spheroid 
culture were connected to adjacent cells though cell-cell junction (arrow). These cell-cell 
junctions were responsible for the densely packed organization of the cells (scale bar: 1 µm). (c) 
Under optical microscope, the morphology of cells cultured in monolayer (scale bar: 400 µm). 
(d) The cell spheroid was stained with Live/dead assay. Under confocal laser microscope, live 
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cells emitted green fluorescence and dead/dying cells emitted red fluorescence (scale bar: 100 
µm). 
 
Next, the internal proliferative status of CHO-K1 spheroids was verified by LIVE/DEAD 
Viability/Cytotoxicity kit. As shown in Figure 5.2d, the cells within a spheroid were clearly 
divided into two populations: live cells emitting green fluorescence at the exterior layers and 
dead/dying cells emitting red fluorescence in the core. These results proved that CHO-K1 
spheroids mimicked in vivo solid tumor properties and cell necrosis could happen within the 
cell spheroids due to the limit of nutrient and oxygen supplies, such as in the center core 
[151–153]. 
5.4.2 Penetration of GL1-siRNA Complexes in Tumor Spheroids 
To understand the distribution of siRNA within tumor spheroids over time, Cy3-labeled 
GAPDH siRNA was used for this study, in which Cy3 emitted red fluorescence after 
excitation. As shown in Figure 3, the GL1-Cy3 labeled siRNA complexes were taken up by 
the cells at the outer layers of the cell spheroid after 24 h incubation (Figure 5.3a). After 48 h 
incubation, the complexes were evident in the deeper layers of the cell spheroid and the red 
fluorescence intensity strongly increased (Figure 5.3b). Cell nuclei were stained with DAPI, 
a nuclear stain reagent emitting blue fluorescence after excitation, to localize the distribution 
of GL1-siRNA complexes. However, in monolayer culture of CHO-K1 cells, GL1 could 
deliver Cy3 labeled siRNA to most of the cells after 4 h treatment. The different cell culture 
models possibly caused this difference. In cell monolayer, GL1-siRNA complexes were 
directly in contact with the cells and entered the cells with ease. However, there are more 
barriers in cell spheroids than in cell monolayer, including three dimensional cell-cell 
interactions, cell-ECM interaction, ECM, mass diffusion limit, which affected the penetration 
of peptide-siRNA complexes. 
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Figure 5.3. Penetration of GL1-Cy3-labeled GAPDH siRNA complexes into CHO-K1 cell 
spheroids 24 h (a) and 48 h (b) post treatment. 
 
Additionally, cellular penetration also depends on the physicochemical characteristics of 
the nanoparticles, such as size, surface charge, and shape. Ma H. et al claimed that the 
positively charged nanoparticles were preferentially retained by the negatively charged ECM 
and taken up by proliferating cells in the exterior layers, and negatively charged 
nanoparticles were not hindered by ECM and taken up by viable cells [154]. However, the 
exact mechanisms for the charge preference are still unclear. They also discovered that with 
the same charge, smaller nanoparticles penetrated more deeply than larger nanoparticles. 
[154,155] This indicated that GL1-siRNA complexes with the size of ~80 nm in diameter and 
positive surface charge could facilitate sufficient siRNA uptake within spheroids and 
monolayer. However, the cellular internalization of siRNA in spheroids was slowed down 
due to the limited intercellular space and cell surface area in spheroids when compared with 
monolayer culture [156].  Thereafter, the cytotoxicity induced by GL1-siRNA complexes 
was evaluated. 
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5.4.3 Cytotoxicity 
 WST-1 assay was used to determine the viability of the spheroids after treatment. As shown 
in Figure 5.4, siRNA alone did not cause cytotoxicity. Cells treated with Lipofectamine 
2000-siRNA complexes exhibited 83% viability. However, cells treated with GL1-siRNA 
complexes achieved >90% viability, suggesting that GL1 is a relatively safe carrier for 
siRNA delivery. 
 
Figure 5.4. Cell viability results of CHO-K1 cells treated with the complexes at different molar 
ratios or peptide alone at the same concentration as peptide in complex with siRNA at 
corresponding molar ratio. (N.T.= non-treated cells, MR=peptide/siRNA molar ratio, 
Lipo=Lipofectamine 2000). Results are expressed as mean ±  standard deviation (n=3). 
 
5.4.4 In Vitro Transfection Efficiency 
In order to evaluate the efficacy of the delivered GAPDH siRNA, RT-PCR measurement of 
GAPDH mRNA level in the CHO-K1 cell spheroids was performed. A scrambled siRNA 
was used as a negative control. The GAPDH mRNA level in each sample was normalized to 
the level measured in cells treated with the negative control. The RT-PCR results exhibited 
an increase in GAPDH gene silencing efficiency in GL1-siRNA complexes treated cells 72 h 
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post transfection. Another housekeeping gene cyclophilin was a control and its mRNA level 
remained relatively stable during the transfection experiments. As shown in Figure 5.5, the 
gene silencing efficiency induced by GL1-siRNA complexes were molar ratio dependent. At 
a molar ratio of 20/1 with siRNA concentration of 100 nM, 13% gene knockdown was 
observed. When increasing the molar ratio to 40/1, the gene knockdown efficiency increased 
to 40%, which is similar to that of Lipofectamine 2000. At an even higher molar ratio of 
60/1, 54% gene knockdown was achieved. The possible reason is that at higher molar ratios, 
higher amount of peptides can protect siRNA longer and lead to higher siRNA uptake. The 
relatively large particle size of Lipofectamine 2000-siRNA complexes possibly limited the 
cellular uptake of siRNA within the multicellular tumor spheroids [157–159], thus leading to 
a relatively low gene silencing efficiency (38%). However, in CHO-K1 monolayer culture, 
Lipofectamine 2000-siRNA complexes achieved 80% GAPDH gene knockdown, which was 
significantly higher than that in 3D culture. This significant difference suggested that the 
culturing environment could strongly affect the biological outcome of the complexes. 
 
Figure 5.5. Gene silencing efficiency in vitro. Silencing of GAPDH gene in CHO-K1 cells was 
evaluated by quantitative real time polymerase chain reaction (qRT-PCR). GAPDH siRNA 
concentration was 100 nM. Lipo was the positive control, and scrambled siRNA was used as the 
negative control. Results are expressed as mean ±  standard deviation (n = 3). 
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5.4.5 In Vivo Tumor Growth Suppression 
If the average weight of mice in a treatment group (after the tumors were removed) decreased 
by more than 15% (self-control) during treatment, indicating drug toxicity, the dosage should 
be reduced and re-tested [160]. Our results show that the body weight of each mouse in each 
group did not change significantly during the experiment (Figure 5.6a).  
 
Figure 5.6. Local treatments with GL1/siRNA complexes inhibit tumor growth in a mouse 
xenograft tumor model. (a) The body weight of each group. Body weights of the mice were 
measured everyday during the treatment. Data shown is the mean value of eight mice in each 
group (n=8). (b) Dissected tumor tissues after treatment. Mice were killed by cervical 
dislocation on the 27th day. Tumors were then separated. Representatives of five treatment 
groups: model, saline, GL1 peptide, naked Bcl-2 siRNA and GL1/siRNA complex. (c) 
Antitumor activity of GL1/siRNA complex in a mouse tumor model. The complexes were 
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administered intratumorally in mice model bearing A549 cancer cells xenografted under the 
skin. The tumor sizes were measured everyday. Model group: non-treated group with injection 
of water alone. Data shown is the mean value of eight mice in each group. ** p<0.05 versus 
model group (n=8). (d) Inhibition of Bcl-2. 
 
To monitor the tumor growth, the diameters of tumors were measured daily, and the tumor 
volume was calculated using the formula provided above. Considering the average value for 
each group (Figure 5.6c), the volumes of the tumors in the model group, saline group and 
GL1 group were similar, and the differences were not significant (p＞0.05). The volumes of 
the tumors in the siRNA group and GL1-siRNA group were significantly smaller than those 
of the other three groups (p＜0.05), and the volume of the tumors in the GL1-siRNA group 
was significantly smaller than that of the siRNA group (p＜0.05). At the end of the 
experiments, tumor tissues were separated and weighed. The tumor weight of GL1-siRNA 
group (0.6291g) is significantly lower than that of saline treated control (1.3281g) and model 
group (1.3551g) with a tumor inhibition rate of 52.6%. The representative tumor of each 
group was shown in Figure 5.6b.  
To demonstrate the tumor growth inhibition was induced by Bcl-2 down regulation in 
tumor cells, the expression of Bcl-2 protein in tumor tissues was detected by Western blot. 
The results are shown in Figure 5.6d, which demonstrates that the expression of Bcl-2 protein 
was inhibited in the siRNA group and the GL1-siRNA group and the inhibition was greater 
in the GL1-siRNA group. Moreover, Bcl-2 protein expression in the saline group and GL1 
group was similar to that of the model group. Due to the local intratumoral injection of 
treatments, there was a decrease in Bcl-2 protein level in the siRNA group. However, the 
GL1-siRNA group achieved a significantly higher inhibition of Bcl-2 protein expression 
(p<0.05), which represented the advantage of utilizing GL1 as a delivery system. 
In the 2D environment, the cell interacts with a basal extracellular “matrix” and with 
surrounding cells through lateral cell-cell junctions. This is very different from in vivo 
conditions where cells are exposed to the 3D environment. Multicellular spheroids are one of 
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the most widely used 3D culture systems and resemble many aspects of the physiological 
conditions within in vivo tumor models.  
Therefore, we developed multicellular CHO-K1 spheroids to study the peptide GL1 
mediated delivery of siRNA. Morphological analysis by light microscopy and SEM 
demonstrated that the CHO-K1 cells formed tightly packed spheroids (Figure 1a, 2a). Within 
the spheroid, the cells were spherical shaped, connections between cells were close and 
compact, and ECMs were observed (Figure 2b). This is close to in vivo tumor tissue, but 
different from monolayer cells (Figure 2c). The cell conditions in the spheroid were 
determined through confocal laser microscopy after staining the cells with Live/Dead assay. 
The results indicated that 6-day cultured CHO-K1 spheroids could be divided into two 
groups (Figure 2d). Outer layer cells of the spheroids made contact with the culture medium 
were highly proliferative and stained green by calcein AM. Inner layer cells of the spheroids 
were apoptotic/necrotic cells and stained red by EthD-1. These results suggested that CHO-
K1 spheroids mimicked in vivo solid tumor properties and cell necrosis could happen within 
the cell spheroids due to the limit of nutrient and oxygen supplies, such as in the center 
core.[151–153]  
The penetration of peptide-Cy3-labeled siRNA complexes to CHO-K1 spheroids was 
investigated via the confocal laser microscopy. The results demonstrated that the penetration 
of the complexes was time dependent (Figure 3). Compared to CHO-K1 cells grown in 
monolayer, cellular uptake of peptide-siRNA complexes in spheroids was much slower, due 
to various barriers such as limited intercellular space and ECMs. The GAPDH gene silencing 
efficiency of peptide-siRNA complexes was molar ratio dependent (Figure 5), whereas 
higher amounts of peptide could protect siRNA longer and enhance the penetration of the 
complexes. Additionally, the peptide-siRNA complexes induced >90% cell viability (Figure 
4), which is higher than that of Lipofectamine 2000-siRNA complexes.  
In order to translate the findings obtained from the in vitro model to the more complex in 
vivo tumor model, we evaluated the antitumor effect of GL1-Bcl-2 siRNA complexes (molar 
ratio: 60/1) in the animal xenograft model. The intratumoral injection of the complexes 
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induced a significant tumor growth inhibition rate (52.6%) through the down regulation of 
Bcl-2 protein expression confirmed through western blot analysis (Figure 6). It is worth 
noting that all of the mice performed their normal activities throughout the experiment, and 
no mice died. After dissecting all of the mice, no abnormal viscera, including the heart, liver, 
spleen, lung, and kidneys was observed, suggesting the complexes are relatively safe to use. 
5.5 Conclusions 
Our studies suggest that MCTS closely mimic the features of tumors in vivo, confirmed 
through the data of characterizations. Utilizing confocal laser scanning microscopy, we 
observed that GL1-siRNA complexes could penetrate into the deeper layers of multicellular 
spheroids over the time.  Taking into account that GL1 achieved marked gene silencing 
efficiency (50%), compared to the commercial transfection reagent, Lipofectamine 2000 
(38%), with minimal cytotoxicity in multicellular tumor spheroids (<10%), and that GL1-
Bcl-2 siRNA complexes enabled significant anti-tumor effects in vivo (52.6%), this indicates 
that GL1 is a highly promising siRNA delivery vector, both in vitro and in vivo. 
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Chapter 6†† 
Effective Small Interfering RNA Delivery In Vitro via A New 
Stearylated Cationic Peptide STR-HK 
 
Abstract 
A crucial bottleneck in RNA interference (RNAi) based gene therapy is the lack of safe and 
efficient delivery systems. Here, a novel siRNA delivery peptide, STR-HK, was constructed 
by conjugating a stearyl end to the N-terminus of the peptide sequence “HHHPKPKRKV”, 
where “PKPKRKV” is an altered sequence of the nucleus localization signal (PKKKRKV) 
and contributes to the cytosol localization of STR-HK-siRNA complexes. Histidine is a 
linker and plays an important role in disrupting the endosomal membrane via the proton 
sponge effect. As expected, STR-HK formed complexes with siRNA with a particle size of 
80-160 nm in diameter and efficiently delivered Cy3 labeled GAPDH siRNA into PC-3 
human prostate cancer cells. The transfection efficiency of STR-HK at molar ratio 60/1 was 
comparable to that of Lipofectamine 2000, one of the most efficient commercially available 
transfection reagents. Furthermore, the STR-HK-siRNA complexes exhibited minimal 
cytotoxicity, which was significantly lower than that of Lipofectamine. Taken together, the 
strategy of conjugating the stearyl moiety with “HHHPKPKRKV” as a non-viral siRNA 
delivery system is advantageous. 
 
 
 
 
                                                      
†† This chapter is based on a paper. B. Chen, R. Pan, D. Askhatova, P. Chen. Effective Small 
Interfering RNA Delivery In Vitro via A New Stearylated Cationic Peptide. International 
Journal of Nanomedicine, 2015, 10:1-12. 
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6.1 Introduction 
RNA interference (RNAi) is a specific cellular post-transcriptional gene silencing 
mechanism, which can be induced by evocation of enzymatic degradation of a corresponding 
mRNA. Double-stranded small interfering RNA (siRNA) consisting of 21-25 nucleotides 
plays an important role in this process. siRNA can be synthesized exogenously and delivered 
to the cytoplasm to be loaded into the RNA-induced silencing complex (RISC). RISC 
induces the siRNA to unwind in a strand specific manner. The sense strand of siRNA is 
cleaved and removed, then the remaining antisense strand of the duplex acts as a guide to 
lead the RISC complex into the complementary sequence of the target mRNA. Upon 
association of the target mRNA with RISC, AGO protein cleaves the mRNA and interrupts 
the translation process.[161–163] Being a potent and highly specific therapeutic strategy, 
siRNAs have been evaluated as potential therapeutic agents for a wide range of gene based 
diseases. However, the major limitations for the use of siRNA are the instability of naked 
siRNA in physiological conditions, the nature of negative charge, and hydrophilicity. 
Currently, various strategies have been applied to improve siRNA’s nuclease resistance 
without interfering with its silencing efficiency [164,165], such as chemical modifications in 
the nucleobases, the phosphate ester backbone, and conjugation with hydrophobic functional 
groups [166]. However, this is very time-consuming and costly. Carrier based strategies have 
been explored as a simple and fast means to protect the siRNA and maximize its therapeutic 
effects.   
A number of delivery carriers have been developed and characterized including peptides 
[167], polymers [168,169], liposomes [170,171], lipids [172,173], and viral vectors [174]. 
Due to the fundamental drawbacks of viral vectors, such as toxicity and immunogenicity, 
non-viral vectors have served as an alternative because of their advantage in inducing 
relatively low toxicity and nearly no immune response [161,162]. Among these non-viral 
vectors, cell penetrating peptides are being increasingly utilized for gene delivery 
[163,175,176]. Researchers have proven that cell penetrating peptide MPG, the peptide 
  91 
derived from both the fusion peptide domain of HIV-1 gp41 protein and the nuclear 
localization sequence (NLS) -‘PKKKRKV’- of SV40, can deliver DNA into the nucleus 
efficiently. NLS plays an essential role in importing DNA into the nucleus.[177] A single 
mutation of a lysine residue to a proline residue (PKPKRKV) in NLS, limits its nuclear 
translocation, but enhances release of the cargo into the cytoplasm, which is helpful for 
siRNA intracellular localization.[178] Recently, stearylation has proven to be successful in 
increasing the transfection efficiency of CPPs for DNA delivery [179–185] or that of PEI for 
siRNA delivery [186]. The increased transfection efficiency is attributed to the enhanced 
compaction of DNA, increased endosomal escape, and higher cellular uptake, which are all 
conferred by the stearyl moiety.  
Having considered the similarity of siRNA and DNA, a novel type of non-viral siRNA 
delivery vector was constructed by introducing a stearyl moiety to the N-terminus of the 
sequence. Three histidine residues serve as a linker between the stearyl moiety and 
“PKPKRKV”. The other reason for using histidine is that it will be helpful for the rapid 
release of siRNA into the cytosol after intracellular uptake. In this report, the 
physicochemical and biological characteristics of this new peptide, STR-HK (C18-
HHHPKPKRKV-NH2), was investigated in order to evaluate its potential for siRNA 
delivery. 
6.2 Materials & Methods 
6.2.1 Materials 
Peptide STR-HK (C18-HHHPKPKRKV-NH2) with a molecular weight of 1500.9 g/mol, was 
synthesized by CanPeptide Inc. with a purity >95% (Quebec, CA). The high performance 
liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) 
characterization of STR-HK is shown in Figure 6.1 and Figure 6.2. SiRNA targeting the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene and Cy3-labeled GAPDH 
siRNA were purchased from Ambion (SilencerTM GAPDH siRNA kit). The siRNA targeting 
eGFP gene, GCGACGUAAACGGCCACAAGU, was purchased from Dharmacon, whose 
antisense sequence is ACUUGUGGCCGUUUACGUCGC and sense sequence is 
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GACGUAAACGGCCACAAGUUC. The negative control siRNA was purchased from 
Ambion. Cell counting kit-8 was used for cell viability test and was purchased from Dojindo 
Molecular Technologies. 
 
Figure 6.1. HPLC data of STR-HK. 
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Figure 6.2. LC-MS data of STR-HK. 
 
6.2.2 Methods 
6.2.2.1 Cell culture 
Human prostate cancer cell line (PC-3) was purchased from the American Type Culture 
Collection. PC-3 cells were grown in F-12K medium (Thermo Scientific, Ottawa, BC, CA) 
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, Oakville, Ontario, CA). 
The cell line was cultured at 37oC in a 5% CO2 atmosphere. 
6.2.2.2 Preparation of STR-HK-siRNA complexes 
The preparation of STR-HK-siRNA complexes in this chapter followed the same procedures 
as presented in chapter 3. 
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6.2.2.3 Agarose gel-shift assay 
This experiment followed the same procedures as presented in chapter 3. 
6.2.2.4 Isothermal titration calorimetry (ITC)  
siRNA condensation was evaluated using isothermal titration calorimetry. The experiments 
were conducted using a Nano-ITC calorimeter (TA Instruments, New Castle, DE, USA). A 
500 µM STR-HK peptide solution and a 10 µM siRNA solution were both prepared in 
RNase-free water. This experiment followed the same procedures as presented in chapter 3. 
6.2.2.5 Particle size and zeta potential 
This experiment followed the same procedures as presented in chapter 3. 
6.2.2.6 Scanning electron microscopy (SEM) 
The morphology of STR-HK-siRNA complexes at a molar ratio of 20/1 was observed under 
SEM. This experiment followed the same procedures as presented in chapter 3. 
 
6.2.2.7 Transmission electron microscopy (TEM) 
TEM was utilized to acquire the morphology of STR-HK-siRNA complexes at molar ratio of 
20/1 with siRNA concentration of 100 nM. Ten µl of the samples was applied to a 400 mesh 
Formva coated copper grid (Canemco-Marivac, Canton de Gore, Canada) for 3-5 min. The 
sample was then washed 5 times with RNase free water and dried over night. Uranyl acetate 
(Electron Microscopy Sciences, USA) was used to stain the samples. An electron micrograph 
of the STR-HK-siRNA complexes was acquired using TEM (Philips CM10 TEM, the 
Netherlands) 
6.2.2.8 Circular dichroism (CD) spectroscopy 
CD was used to investigate the secondary structure of the peptide and its change after 
forming a complex with siRNA. This experiment followed the same procedures as presented 
in chapter 3. 
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6.2.2.9 Cytotoxicity 
The cytotoxicity of peptide-siRNA complexes was determined by the Cell Counting Kit-8 
(CCK-8) assay. In brief, cells were seeded at 10,000 cells/well in clear, flat-bottomed, 96-
well plates (Costar) 24 h before treatment. After being washed, 100 µl of Opti-MEM that 
contained peptide-siRNA complexes at different molar ratios was added to the wells and 
incubated for 4 h. Thereafter, 50 µl of 30% serum containing medium was added, and the 
cytotoxicity of the relevant reagents was determined by the CCK-8 assay after 24 h and 48 h. 
Then, the cultures were removed from the incubator and the absorbance at 570 nm was read 
on a plate reader (BMG, FLUOstar OPTIMA, Germany). The background absorbance of the 
multiwell plates at 690 nm was determined and subtracted from the 570 nm measurement. 
The results obtained from triplicate wells were averaged and normalized to the value 
obtained from the non-treated cells. 
6.2.2.10 Cellular uptake 
PC-3 cells (80,000/well) were cultured in a 24 well plate 24 h before treatment. The cells 
were incubated with STR-HK-Cy3-labeled GAPDH siRNA complexes at a molar ratio of 
40/1 for 4 h. Lipofectamine 2000-Cy3-labeled GAPDH siRNA complexes was a positive 
control here. Thereafter, the cells were washed three times with PBS and then fixed by 4% 
paraformaldehyde (PFA). The nucleus of the cell was stained by DAPI. Images were taken 
with a fluorescence microscope. To quantify the cellular uptake of peptide-siRNA 
complexes, PC-3 cells (80,000/well) were cultured in 24-well plates 24 h before treatment. 
The cells were incubated with peptide-Cy3-labeled GAPDH siRNA complexes at different 
molar ratios for 4 h. Next, cells were rinsed with PBS and then washed with heparin (10 
U/ml). After thorough washing, trypsin-EDTA was added to detach the cells from the plate. 
The cells were re-suspended in 4% PFA for analysis using fluorescence activated cell sorting 
(BD Biosciences, BD FACSVantage SE Cell Sorter, CA). 
6.2.2.11 In vitro transfection 
PC-3 cells were seeded at 80,000 cells/well in 24-well plates 24 h before treatment. Cells 
were treated with peptide-siRNA complexes in 300 µl of Opti-MEM at different molar ratios 
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for 4h. Thereafter, 300 µl medium containing 20% FBS was added to each well. After 
incubation of 48 h, cells were washed and collected for qRT-PCR analysis. 
Firstly, the total RNA was extracted from the treated cells using the SV Total RNA 
Isolation System (Promega, Sunnyvale, CA, USA). A Nanodrop (Thermo Scientific, 
Nanodrop spectrophotometer ND-1000, Ottawa, BC, CA) was used to determine the RNA 
concentrations. The RNA samples were reverse-transcribed into cDNA using a Bio-Rad 
iScript cDNA synthesis kit according to the manufacturer’s protocol. After the cDNA was 
synthesized, PCR was performed with Brilliant II fast SYBR Green QPCR Master Mix 
(Agilent Technologies, Wilmington, DE, USA) using an Mx3005PTM real time PCR System 
(Agilent Technologies, Santa Clara, CA, USA). The sequences of the primers used for the 
human GAPDH gene: 5’-GAAATCCCATCACCATCTTCCAG-3’ and 5’-
GAGCCCCAGCCTTCTCCATG-3’ (Sigma-Aldrich, Oakville, ON, CA). Cyclophilin, a 
housekeeping gene, was used as an internal control to normalize the GAPDH gene 
expression. Human cyclophilin mRNA was amplified using the following primers: 5’-
GGTGATCTTTGGTCTCTTCGG-3’ and 5’-TATATGCTCTTTCCTCCTGTG-3’ (Sigma, 
Oakville, Ontario, CA).  
6.3 Statistical Analysis 
Results were expressed as mean values ± SD. Data were analyzed by two tailed T test and 
only p-values < 0.05 were considered statistically significant. 
6.4 Results 
6.4.1 Characterization of Peptide-siRNA Complexes 
Agarose gel shift assay was applied to detect the loading capacity of STR-HK. Basic amino 
acids such as arginine and lysine was protonated and able to interact with the negatively 
charged phosphate groups on siRNA sugar rings through electrostatic interactions. STR-HK 
contains four positively charged residues: three arginine and one lysine so as to strongly 
interact with siRNA. In the agarose gel electrophoresis experiment, when voltage is applied, 
free siRNA will move towards the positive electrode. As shown in Figure 6.3, the band 
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produced at higher molar ratio was less dark than band produced by siRNA alone. At molar 
ratios above 15/1, no free siRNA was detected on the agarose gel, indicating that siRNA 
molecules were completely complexed with STR-HK. This suggests that at molar ratios 
higher than 15/1, there is sufficient STR-HK to neutralize the negative charge of siRNA and 
form complexes with siRNA. 
 
Figure 6.3. Binding ability of siRNA to STR-HK studied by agarose gel-shift assay. The formed 
STR-HK-siRNA complexes, stained with ehidium bromide, were investigated by electrophoresis 
on agarose gel (1.2% wt/vol). siRNAs, targeting eGFP gene, were complexed with STR-HK at a 
series of molar ratios from 1/1 to 80/1. Lane 1 was siRNA control, and lanes 2-8 indicated 
correlated molar ratios. The amount of siRNA was 300 ng. 
 
To evaluate the stoichiometry between STR-HK and siRNA and the thermodynamic 
parameters during the condensation process, ITC was employed. As shown in Figure 6.4, the 
heat exchange during the titration of siRNA by STR-HK (in RNase-free water) was detected 
by the machine and output as raw data. By fitting the raw ITC data (upper panel of Figure 
6.4) to a single-site model (lower panel of Figure 6.4), the thermodynamic parameters of the 
interaction were obtained and listed in Table 6.1. 
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Figure 6.4. Calorimetric titration of siRNA with STR-HK at 25 oC in RNase-free water at pH 6. 
(a) Corrected thermogram of calorimetric titration of siRNA with STR-HK, (b) Binding 
analysis of siRNA with STR-HK by fitting the raw data with an independent model. STR-HK 
concentration was 500 µM and siRNA concentration was 10 µM. 
Table 6.1. Thermodynamic parameters when titrating siRNA with STR-HK in water.  
Ka (1/M) ΔH (kJ/mol) n Kd (M) ΔS (J/(mol⋅K)) 
3.726⋅105   -8.347  10 2.684⋅10-6  78.67 
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The obtained molar stoichiometry was 10, which implied that 10 moles of STR-HK could 
condense 1 mole of siRNA. This number was very close to the theoretical value of 10.5, 
considering that the STR-HK peptide contains 4 positively charged residues (Arginine and 
Lysine), and there are 21 pairs of negatively charged nucleotides in the siRNA molecule. 
With an enthalpy of -8.35 kJ/mol, ΔS of 78.67 J/(mol⋅K), and entropy of -23.44 kJ/mol, the 
binding was predominantly entropy-driven. Moreover, ΔG calculated using the equation 
ΔG=ΔH-TΔS was equal to -31.79 kJ/mol, which indicated that STR-HK and siRNA 
assembled spontaneously [102,103].  
The particle size and zeta potential of the complexes were measured to gain an 
understanding of  the physicochemical properties of STR-HK-siRNA complexes. As shown 
in Figure 5a, overall particle sizes remained in the range of 80-160 nm. From a molar ratio 
10/1 to 60/1 (peptide/siRNA) particle size increased. However, at a molar ratio of 60/1, 
particle size slightly decreased and was similar to that of a molar ratio of 40/1. According to 
the graphs of size distribution by intensity (Figure 6.5), the possible reason for this 
phenomenon was that at molar ratio of 60/1, excess peptides formed smaller nanoparticles, 
and thus decreased the average size. However, the wider size distribution at MR 60/1 resulted 
in a higher variation. 
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Figure 6.5. (a) The hydrodynamic diameter and (b) zeta potential of the STR-HK-siRNA 
complexes at different molar ratios were measured by dynamic light scattering (DLS). The 
lower two graphs are the size distribution by intensity of STR-HK-siRNA complexes at a molar 
ratio of 40/1 and 60/1. The siRNA concentration was fixed as 100 nM. At different molar ratios, 
the amount of STR-HK was adjusted. Results are expressed as mean ±  standard deviation 
(n=3). The difference of size distribution at a molar ratio of 40/1 and 60/1 is not statistically 
significant. 
 As expected, the zeta potential of complexes increased with increasing molar ratios 
(Figure 6.5b) due to the addition of excess positively charged peptides. Interestingly, at a 
molar ratio of 10/1, the surface charge of STR-HK-siRNA complexes was slightly negative (-
13 mV), and at a slightly higher molar ratio (15/1), it turned out to be positive (15.2 mV). 
This interesting phenomenon indicated that siRNA molecules were not fully complexed at a 
molar ratio of 10/1 but could be so by slightly increasing the molar ratio. 
Additionally, a SEM image of the complexes formed by STR-HK with siRNAs at a molar 
ratio of 20/1 is shown in Figure 6.6a. The graph shows that the STR-HK-siRNA complexes 
displayed a smooth and spherical shape with the size around 100 nm. The morphology of the 
complex at molar ratio of 20/1 was also examined by TEM, shown in Figure 6.6c. The 
electron micrograph exhibited spherical shape with the size of approximately 100 nm. The 
particle size acquired from SEM and TEM experiments was consistent with the DLS result. 
More importantly, this morphology indicates that STR-HK could condense siRNA to regular 
nanoparticles.  
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Figure 6.6. (a) Morphology of STR-HK-siRNA complexes at a molar ratio of 20/1, where siRNA 
concentration was 100 nM. (b) CD spectra of STR-HK alone and STR-HK-siRNA at different 
molar ratios. STR-HK concentration was fixed at 30 µM and STR-HK-siRNA complexes were 
formulated at molar ratios of 5/1 and 10/1. (c) Morphology of STR-HK-siRNA complexes at a 
molar ratio of 20/1 with siRNA concentration of 100 nM, scale bar: 100 nm. 
 
Furthermore, secondary structure is an important feature of peptides. From the changes of 
secondary structure, it can prove the interactions of STR-HK and siRNAs at a molecular 
level. As shown in Figure 6.6b, STR-HK alone in water exhibited a random coil structure 
with a minimum at 202 nm. After adding siRNAs to the peptide solution to form complexes 
at a molar ratio of 10/1, a clear conformational change occurred and a minimum at 213 nm 
was observed, which implied a typical β sheet structure. By adding more siRNAs to attain 
the molar ratio of 5/1, the absolute values of the minimum spectra at 213 nm and the 
maximum spectra at 190 nm were increased. The results indicated that upon interaction with 
siRNAs, STR-HK adopted a more ordered secondary structure-β sheet instead of a randomly 
folded structure. The conformational change also revealed the flexibility of STR-HK when it 
formed regular nanoparticles with siRNAs. 
6.4.2 Cytotoxicity of STR-HK-siRNA Complexes 
The cytotoxicity of peptide-siRNA complexes was evaluated by the CCK-8 assay, and 
Lipofectamine 2000 (Lipo) was used as the control. As shown in Figure 6.7a, after 24 h of 
treatment, both peptide alone and Lipo alone caused almost no cytotoxicity. The cytotoxicity 
of STR-HK-siRNA complexes at molar ratios from 20/1 to 60/1 was less than 5%. However, 
the cytotoxicity of STR-HK-siRNA complexes was significantly lower than that of Lipo after 
24 h of treatment. To evaluate the long-term cytotoxicity of the complexes, cytotoxicity after 
48 h of treatment was also studied. Figure 7b shows that the cytotoxicity of each treatment 
followed a similar trend to that after 24 h of treatment. These results indicated that STR-HK 
did not cause either short-term or long-term cytotoxicity, which was superior to Lipo in this 
criterion. 
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Figure 6.7. Cell viability results of PC-3 cells treated with, peptide-siRNA complexes (siRNA 
concentration: 100 nM) at different molar ratios or peptide alone at corresponding molar ratio. 
(NT= Non treated, MR=peptide/siRNA molar ratio, Lipo=Lipofectamine 2000). (a) Cell 
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viability after 24 h treatment; (b) Cell viability after 48 h treatment. Results are expressed as 
mean ±  standard deviation (n = 3). 
 
6.4.3 Cellular Uptake of STR-HK-siRNA Complexes 
The cellular uptake of STR-HK-Cy3-labeled siRNAs complexes was studied with 
fluorescence microscopy and FACS. As shown in Figure 6.8, most cells treated with 
Lipofectamine 2000-Cy3-labeled siRNA complexes displayed red dots in their cytosol. In the 
cells treated with STR-HK-siRNA complexes, siRNAs were localized to regions in close 
proximity to the nuclear membrane and were distributed in a non-homogeneous pattern at the 
periphery of the nucleus, which indicated the possibility of endocytotic delivery [107]. More 
interestingly, the cellular uptake of STR-HK-siRNA complexes was molar ratio dependent 
and was almost equivalent to that of the Lipo-siRNA complexes at a molar ratio of 60/1 
(Figure 6.9). These data indicated that STR-HK could efficiently deliver sufficient Cy3-
labeled siRNAs into PC-3 cells. 
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Figure 6.8. Fluorescence microscope image of STR-HK-siRNA complexes at molar ratio 60/1. 
The red fluorescence indicated Cy3 labeled siRNA, blue fluorescence represented DAPI stained 
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nuclei. NT was non treated cells, used as a negative control. Cells treated with Lipo-siRNA 
complexes were a postive control. The scale bar was 100 µm. 
 
Figure 6.9. FACS results of cellular uptake of siRNA. Non-treated sample was negative control; 
Lipo-siRNA complexes were positive control. Cy3 labeled GAPDH siRNA was used here. 
siRNA concentration was 100 nM in both experiments. * P value<0.05, the difference of cellular 
uptake efficiency of siRNA at a molar ratio of 40/1 and 60/1 is statistically significant. 
 
6.4.4 In Vitro Transfection of Peptide-siRNA Complexes 
To evaluate the transfection efficiency of STR-HK, PC-3 cells were treated with the 
complexes formed by STR-HK with GAPDH siRNA at different molar ratios. As shown in 
Figure 6.10, the transfection efficiency of STR-HK increased with the increasing molar ratios 
and almost reached the similar level of Lipo at the molar ratio of 60/1. 
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Figure 6.10. Gene silencing efficiency in vitro. Silencing of GAPDH gene in PC-3 cells was 
evaluated by quantitative real time polymerase chain reaction (qRT-PCR). GAPDH siRNA 
concentration was 100 nM. Lipo was the positive control, and scrambled siRNA was used as the 
negative control. Results are expressed as mean ±  standard deviation (n = 3). 
 
6.5 Discussion 
siRNA molecules hold great therapeutic potential  for the development of RNAi based drugs 
to interfere with various diseases.[179,180,187–189] However, siRNA therapeutics were 
limited by their low bioavailability due to their physicochemical properties (negative charges, 
large molecular weight, and size) and instability with plasma half-life of about 10 min 
[10,111,190], immune stimulation when administered systemically [191], and possible off-
target effects due to partial nucleotide sequence match between the siRNA and off-target 
mRNA [192]. Seeking efficient delivery systems for these molecules is a prerequisite for 
successful gene therapy. CPPs as one group of nonviral peptide-based delivery vectors have 
attracted more and more attention due to their high internalization efficiency, low 
cytotoxicity, and flexible structural design.[187,193,194] Recently, a handful of papers have 
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shown that stearylation is a successful strategy to enhance the transfection efficiency of CPPs 
mostly for DNA delivery. Several delivery systems have incorporated this strategy for 
siRNA delivery [195]. Considering the similarities and differences between DNA/plasmid 
and siRNA, a novel siRNA delivery vector was constructed by the conjugation of stearic acid 
to the N-terminus of the sequence ”HHHPKPKRKV”, where “PKPKRKV” is a cytoplasm 
localization sequence. Our result demonstrated that after cellular uptake, the Cy3-labeled 
siRNAs were localized in the cytosol and distributed in a heterogeneous pattern (Figure 8), 
which indicated the possibility of siRNA uptake via an endocytotic pathway [107]. 
The formation of stable and small nanoparticles for CPP-siRNA complexes is undoubtedly 
an important feature to mediate high transfection efficiency.[122] The result of Agarose gel 
shift assay suggested that STR-HK at molar ratios above 15/1 was sufficient to neutralize the 
negative charge of siRNA and form complexes with siRNA. The high affinity of STR-HK 
for siRNA (Kd : 2.68E-6 M) is essentially associated with electrostatic interactions involving 
arginine, lysine residues, and siRNA molecules. Moreover, ITC data revealed that the 
interaction between STR-HK and siRNA was thermodynamically favored, and the driving 
forces include hydrophobic interaction among stearyl moieties and hydrogen bonding among 
amino acid residues when the peptide forms β sheet secondary structure. The conformational 
change of STR-HK from random coil to β sheet secondary structure upon the formation of 
STR-HK-siRNA complexes indicated that STR-HK represented a more stable structure when 
forming complexes with siRNA than peptide alone. Moreover, the stable complexes protect 
siRNA molecules without affecting their silencing efficiency.  
The SEM image and TEM image (Figure 6) showed that STR-HK-siRNA complexes 
displayed a spherical shape. Ideally, to target tumors, the diameter of CPPs-siRNA particles 
should not exceed 100 - 300 nm for efficient uptake.[187] In this report, the particle size of 
STR-HK-siRNA complexes at a molar ratio of  >15/1 was in the range of 100 - 160 nm and 
fulfilled the criteria of size required for an efficient transfection agent. At a molar ratio of 
10/1, STR-HK-siRNA complexes displayed a slightly negative surface charge (-13 mV), 
indicating the surface of the complex was not fully covered by positive charged peptide. At a 
molar ratio of 15/1, the surface charge of the complex increased to 15 mV, implying that the 
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surface of the complex was fully covered by peptide; at even a higher molar ratio, the surface 
charge of the complex increased to 42 mV (at MR 60/1). The net positive surface charge 
could reduce the aggregation of the complexes and enhance the affinity of the complexes 
with the negatively charged cell membrane via electrostatic interaction [95], thus, potentially 
increasing the siRNA delivery efficiency. The quantified cellular uptake of Cy3-labeled 
siRNA showed that at a molar ratio of 20/1, the uptake of Cy3-labeled siRNA was 14 %, 
however, at a molar ratio of 40/1, it increased to 79%. This significant change was probably 
due to the increase of the net positive surface charge and the content of stearyl moiety that 
enhances the interaction of the complex and the lipid bilayer via hydrophobic force. In 
addition, at a molar ratio of 60/1, the uptake efficiency increased to 87%, which is similar to 
that of Lipo but significantly higher than that at a molar ratio of 40/1, implying that 
optimization of the molar ratio for siRNA delivery is crucial.  
After STR-HK-siRNA complexes entered the cytoplasm, the stearyl moiety could disrupt 
the endosomal membrane through hydrophobic interaction with the lipid bilayer and the 
histidine residues could induce the proton sponge effect, leading to the rupture of the 
endosomal membrane to facilitate the endosomal release of siRNA.[87] The results showed 
that the transfection efficiency was consistent with the cellular uptake efficiency at various 
molar ratios. At a molar ratio of 60/1, STR-HK achieved a similar transfection level to that 
obtained with Lipo. The significant difference in GAPDH transfection level at a molar ratio 
of 40/1 and 60/1 is possibly caused by the significant difference in siRNA uptake and 
different amount of stearyl moiety and histidine in the complex formulation that affected the 
endosome release of siRNA. Furthermore, the cytotoxicity of STR-HK was less than 5%, 
which was significantly lower than that of Lipo. Taken together, a schematic of the uptake of 
STR-HK-siRNA complex and its endosomal release was proposed (Figure 6.11). Moreover, 
Effective in vivo RNAi was achieved in a human non-small lung tumor xenograft model 
through intratumoral injection of the STR-HK-Bcl-2 siRNA complexes (molar ratio: 60/1). 
STR-HK-Bcl-2 siRNA complexes resulted in a tumor inhibition rate of 63%±3 via 
downregulation of Bcl-2 protein in mice (data not reported). 
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Figure 6.11. The schematic of STR-HK-siRNA complex uptake and endosomal release. 
 
6.6 Conclusions 
In this study, a novel siRNA delivery vector was constructed by coupling stearic acid to the 
N-terminus of “HHHPKPKRKV”. Our results demonstrated that STR-HK formed stable 
complexes with siRNA via non-covalent interactions and mediated efficient delivery of 
siRNA to PC-3 cells. These results, with the fact that STR-HK induced minimal cytotoxicity 
while achieving comparable gene silencing efficiency to Lipofectamine 2000, prove that 
STR-HK is a promising vector for siRNA delivery. 
 
 
  112 
Chapter 7 
Original Contributions and Recommendations 
 
7.1  Original Contributions to Research 
This thesis focuses on characterization and evaluation of the three newly designed peptides 
as potential siRNA delivery systems. These three peptides were designed according to the 
following strategies: (1) modification of the amphipathic, cationic peptide C6 with 
tryptophan and histidine in the sequence; (2) adoption of parts of peptides CADY and C6M3 
along with addition of an amphipilic segment; (3) conjugation of a stearyl moiety to peptide 
sequence. This thesis includes: (i) characterize physicochemical properties of peptide-siRNA 
complexes, such as size, charge, secondary structure; (ii) investigate the delivery efficiency, 
gene silencing effect, and cytotoxicity induced by the peptide-siRNA complexes; (iii) 
establish multicellular tumor spheroids to examine peptide GL1’s potential as siRNA 
delivery systems; (iv) evaluate siRNA therapeutic effects in an animal xenograft tumor 
model. 
 
Characterization of a Histidine Containing Amphipathic, Cationic Peptide C6M3 for 
siRNA Delivery 
C6M3, an 18-mer-amphipathic peptide, formed complexes with siRNA exhibiting small 
particle sizes (<100 nm). C6M3 adopted helical secondary structure in water and became 
more so upon binding to siRNA. Zeta potential and agarose gel experiments showed the 
ability of C6M3 to completely encapsulate siRNA at molar ratio of 10/1. ITC data revealed 
that the stoichiometry between C6M3 and siRNA is 7/1, which is consistent with the 
theoretical value considering each peptide consists of 6 positive charge residues (R) and 
siRNA contains 21 negative charge base pairs. However, FACS results revealed that higher 
molar ratios were required to achieve better siRNA uptake efficiency. Western blot 
experiment and cell viability data showed that C6M3-siRNA complexes induced 67% 
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inhibition of GAPDH protein expression with minimal cytotoxicity (<10%). These data 
demonstrate that C6M3 is a promising carrier for siRNA delivery and the modification 
strategy is useful. 
 
Design and Characterization of an Amphipathic, Cationic Peptide GL1 for siRNA 
Delivery in Monolayer Culture 
In this study, we have investigated the physicochemical characteristics of the peptide GL1, 
and evaluated its siRNA delivery efficiency and cellular toxicity on the CHO-K1 cell line. 
The major conclusions include the following: GL1 could form complexes with siRNA cargo 
at molar ratio ~10/1 mainly via electrostatic interaction and hydrophobic interaction; GL1 
could spontaneously condense siRNA to form spherical particles with sizes on the nanoscale 
(80-100 nm); GL1 adopted α-helical secondary structure and became more so upon 
interaction with siRNA molecules to form stable complexes; at molar ratio 40/1, GL1 
achieved higher cellular uptake of Cy3-labeled siRNA (95%) than Lipofectamine 2000 in 
serum free environment and retained the same level of uptake as Lipofectamine 2000 (84%) 
with the presence of serum; in all the studied molar ratios, GL1 achieved higher cellular 
viability (>85%) compared to Lipofectamine 2000 (~70%). Therefore, GL1 demonstrated the 
potential as a vector for siRNA delivery. 
 
Evaluation of the Potential of GL1 Peptide for siRNA Delivery in Multicellular Tumor 
Spheroids and In Vivo 
Our studies suggest that MCTS closely mimic the features of tumors in vivo, confirmed 
through the morphologic characterizations. Utilizing confocal laser scanning microscopy, we 
observed that GL1-siRNA complexes could penetrate into the deeper layers of MCTS over 
the time.  Taking into account that GL1 achieved marked gene silencing efficiency (50%), 
compared to the commercial transfection reagent, Lipofectamine 2000 (38%), with minimal 
cytotoxicity in multicellular tumor spheroids (<10%), and that GL1-Bcl-2 siRNA complexes 
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enabled significant anti-tumor effects in vivo (52.6%), this indicates that GL1 is a highly 
promising siRNA delivery vector, both in vitro and in vivo. 
 
Characterization and Investigation of a Stearylated Cationic Peptide STR-HK for 
siRNA Delivery 
In this study, a novel siRNA delivery vector was constructed by coupling stearic acid to the 
N-terminus of “HHHPKPKRKV”. Our results demonstrated that STR-HK formed stable 
complexes with siRNA via non-covalent interactions and mediated efficient delivery of 
siRNA to PC-3 cells. These results, with the fact that STR-HK induced minimal cytotoxicity 
while achieving comparable gene silencing efficiency to Lipofectamine 2000, prove that 
STR-HK is a promising vector for siRNA delivery. 
 
7.2  Recommendations 
 
Based on the studies carried out in this research, the following recommendations for future 
studies are proposed: 
1. Conjugating cell targeting peptides (CTPs) motifs with these three peptides or their 
modified versions to determine the targeting efficiency of the complexes in vitro and 
in vivo 
2. Applying TEM and histology to characterize the internal structure of MCTS and 
FACS to quantify the uptake of siRNA in MCTS 
3. Co-culture the normal cells and cancer cells in 3D to closely mimic the tumor 
microenvironment and evaluating the efficiency of the complexes in this co-culture 
MCTS 
4. Investigate the biocompatibility and serum stability of these three peptides 
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Appendix A††† 
An Amphipathic, Cationic Peptide mediated siRNA Delivery in 3D 
Culture 
Purpose: RNA interference is a natural regulatory process where small, double-stranded 
RNA molecules (typically 21-25 nucleotides) turn off specific genes in a biological cell. 
siRNA therapeutic has been hampered by its hydrophilicity, negative charge, and sensitivity 
to enzyme degradation. Thus, a safe and effective delivery system is mandatory. Our group 
has designed and characterized an amphipathic, cationic peptide (STR-H16R8), which can 
achieve pronounced siRNA uptake and gene silencing in monolayer culture. However, due to 
the lack of characteristics present in live tissues, the preliminary data generated in monolayer 
cultures may not be predictive as that in vivo. Therefore, a 3D cell culture model mimicking 
the in vivo tumors is utilized here to evaluate the cytotoxicity and gene silencing efficiency of 
STR-H16R8-siRNA complexes.  
Methods: The 3D culture model of A549 cells was established using hanging drop method 
and characterized with light microscopy, confocal microscopy, and scanning electron 
microscopy. The cytotoxicity and gene silencing efficiency of STR-H16R8-siRNA 
complexes were quantified with WST-1 assay and qRT-PCR respectively. 
Results: A549 cells in 3D culture closely mimicked the properties of tumors proven through 
microscopic characterizations. STR-H16R8-siRNA complexes induced significant Bcl-2 
gene silencing efficiency with minimal cytotoxicity. Note that the complexes achieved lower 
gene silencing efficiency in 3D than that in 2D, possibly because of the complex 
microenvironment in 3D culture. 
Conclusion: This data provides evidence of the differences in delivering siRNA to 3D cell 
culture model, comparing to monolayer cell cultures. The simple and reproducible 3D cell 
culture model introduced here is a useful system for evaluating the future gene delivery 
systems. 
                                                      
††† This Appendix is based on a conference Abstract. Baoling Chen, P. Chen. An 
Amphipathic, Cationic Peptide mediated siRNA Delivery in 3D culture. Journal of Pharmacy 
& Pharmaceutical Sciences, 2015, accepted.  
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Appendix B  
GL Family Peptides Screening 
CHO-K1 cells were seeded in a 96-well plate with 5,000 cells/well one day before 
transfection. 24 h later, the peptide/siRNA complexes containing GAPDH siRNA or negative 
control siRNA were prepared in Opti-MEM and added to each well in quintuplicate giving a 
final siRNA concentration of 50 nM. After 4 h of incubation at 37°C, equal volume of 
medium with 20% FBS were added to the cells. After 48 h, the GAPDH enzyme activity was 
detected using KDalert™ GAPDH assay kit (Life Technologies, Burlington, Canada) 
according to the manufacturer’s protocol.  
GAPDH is a tetrameric enzyme, composed of 36 kD protein subunits. It catalyzes the 
oxidative phosphorylation of glyceraldehyde-3-phosphate (G-3-P) to bisphosphoglycerate 
(BPG): 
G !3!P +PO4!2 + NAD+ GAPDH" #"" BPG + NADH +H +  
The KDalert GAPDH Assay measures the conversion of NAD+ to NADH by GAPDH in 
the presence of phosphate and G-3-P. Under the recommended assay conditions, the rate of 
NADH production is proportional to the amount of GAPDH enzyme present. Thus, this assay 
can be used to determine the amount of GAPDH protein in a sample. The increase of 
fluorescence intensity was measured with a FLUOstar OPTIMA microplate reader (BMG 
Labtech, Ortenberg, Germany) with excitation wavelength at 560 nm and emission 
wavelength at 590 nm. The GAPDH gene knockdown efficiency was expressed as 100% - 
the fluorescence intensity of cells treated with GAPDH siRNA/ the cells treated with 
negative control siRNA. The peptides used here were listed in Table 1. The GAPDH gene 
silencing efficiency at protein level induced by peptide-siRNA complexes at molar ratio 40/1 
with siRNA concentration of 50 nM was shown in Figure 1. 
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Table 4.2. GL family peptides. 
Name Sequence 
GL1 Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2 
GL2 Ac-GLWRASWLKAWLASNWHKKHRLLR-NH2 
GL3 Ac-GLWGAWFIEGWEGMIDGRRLLRLLR-NH2 
GL4 Ac-GLWRASWLKAFLASNWHKKLHKK-NH2 
 
 
 
 
Figure 1. GAPDH gene silencing efficiency at protein level.48 h post transfection, the cells was 
disrupted in lysis buffer before adding KDalert master mix. The fluorescence intensity was read on a 
plate reader at 590 nm. The molar ratio used here was 40/1 (peptide/siRNA) with siRNA 
concentration of 50 nM (n=5). 
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Figure 2. GAPDH gene silencing efficiency at mRNA level determined with real time PCR in CHO 
cells. GL1-siRNA complexes at molar ratio 40/1 induced gene silencing efficiency at 24 h, 48 h, and 
72 h post transcription. 
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Appendix C 
Delivery Efficacy of STR-HK Peptide in CHO-K1 Cells 
The detailed procedures are described in sections 4.2.2.8, 4.2.2.9, and 4.2.2.10. The results 
are shown below. 
 
 
Figure 1. Cellular uptake of siRNA quantified by FACS. Non-treated sample was negative control; 
Lipo-siRNA complexes were positive control. Cy3 labeled GAPDH siRNA was used here with a 
concentration of 50 nM. (NT= Non-treated, MR=peptide/siRNA molar ratio, Lipo=Lipofectamine 
2000). Results are expressed as mean ± standard deviation (n=3).  
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Figure 2. Gene silencing efficiency in vitro. Silencing of GAPDH gene in CHO-K1 cells was 
evaluated by quantitative real time polymerase chain reaction (qRT-PCR). GAPDH siRNA 
concentration was 50 nM. Lipo was the positive control, and scrambled siRNA was used as the 
negative control. Results are expressed as mean ± standard deviation (n = 3).  
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Figure 3. Cell viability results of CHO-K1 cells treated with naked Lipofectamine 2000 or GL1, and 
the complexes with siRNA (50 nM) at different molar ratios. (NT= Non-treated, MR=peptide/siRNA 
molar ratio, Lipo=Lipofectamine 2000). Results are expressed as mean ± standard deviation (n=3).
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Appendix D 
HPLC & LC-MS Data of GL1 Peptide and C6M3 Peptide 
 
Figure 1. HPLC chromatogram of GL1 peptide. HPLC conditions: Waters 600 Multi-
Solvent System, solvent A is 0.1% TFA/ACN, solvent B is 0.1% TFA/H2O, column: Vydac 
Protein & Peptides C18, 5u, 4.6x250 mm, flow rate: 1 mL/min. 
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Figure 2. LC-MS data of GL1 peptide. The charge on the ion is 1+. The peak with the highest 
value for m/z indicates the desired compound (Peptide+H)+ and the value (3124.22) is the 
relative formula mass of the compound. 
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Figure 3. HPLC chromatogram of C6M3 peptide. HPLC conditions: Waters 600 Multi-
Solvent System, solvent A is 0.1% TFA/ACN, solvent B is 0.1% TFA/H2O, column: Vydac 
Protein & Peptides C18, 5u, 4.6x250 mm, flow rate: 1 mL/min. 
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Figure 4. LC-MS data of C6M3 peptide. The charge on the ion is 1+. The peak with the 
highest value for m/z indicates the desired compound (Peptide+H)+ and the value (2622.52) 
is the relative formula mass of the compound.
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